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RESUMO 
  
Racional:	A insuficiência cardíaca com fração de ejeção preservada 
(ICFEP)	continua refratária às terapias disponíveis, sendo que as diretrizes 
atuais de tratamento destacando a importância de se concentrar na melhoria do 
bem-estar do paciente ou de outras componentes relacionadas à saúde.	Há 
também uma crescente	consciencialização sobre a	necessidade de novas 
abordagens, não só para o tratamento da ICFEP, mas também para sua 
prevenção, através da identificação precoce e da gestão de fatores de risco 
modificáveis.	A aptidão física ou atividade física (AF) vem sendo reconhecidas 
como importantes fatores de risco modificáveis para a prevenção da ICFEP e 
para a gestão dos sintomas cardinais, como a intolerância ao exercício e a 
qualidade de vida (QV).	Do ponto de vista clínico, a aptidão física e a AF podem 
ser consideradas importantes alvos para otimizar os cuidados de saúde desses 
pacientes.	No entanto, existem algumas lacunas neste campo que tornam 
desafiante o desenvolvimento de	intervenções focadas na aptidão física e na AF. 
Primeiro, sendo a aptidão física um constructo multidimensional, é importante 
entender como a ICFEP afeta das diferentes componentes da aptidão física 
e	qual delas é mais representativa das componentes relacionados à 
saúde.	Segundo, para um melhor aconselhamento e prescrição de AF para estes 
doentes, é essencial que os instrumentos utilizados para medir os níveis de AF 
sejam precisos e confiáveis.	Embora o uso de questionários possa ser de fácil 
aplicação na prática clínica, ainda não se sabe se a AF auto reportada se 
correlaciona com a AF objetivamente medida em pacientes com 
ICFEP.	Terceiro, embora	haja alguma evidência de que o exercício físico possa 
melhorar a função diastólica em pacientes com ICFEP,	os mecanismos 
subjacentes a essas	mudanças	permanecem mal compreendidos.		
Objetivo:	No presente trabalho propomos: i) estudar a associação entre os 
diferentes componentes da aptidão física e as dimensões da QV em pacientes 
com ICFEP;	ii) examinar quais das componentes da aptidão física estão 
independentemente relacionados a diferentes dimensões da QV;	iii) determinar 
a validade do Questionário Internacional de AF (IPAQ) comparado com medidas 
objetivas derivadas da acelerometria em pacientes com ICFEP;	iv) descrever os 
padrões diários de AF e tempo sedentário, e avaliar quais padrões estão melhor 
associados aos indicadores prognósticos;	v) avaliar os	efeitos do exercício físico 
na função e estrutura do ventrículo esquerdo (VE), e	alterações 
moleculares	subjacentes, utilizando um modelo animal de ICFEP com ratos 
obesos ZSF1.		
Métodos:	Para atingir os objetivos propostos, avaliamos	 24 pacientes com 
ICFEP	(Estudo I e II).	Foi avaliada a aptidão física [equilíbrio dinâmico e 
mobilidade (8-foot up and go), força dos membros superiores (força de preensão 
manual), aptidão cardiorrespiratória (6 minutos de marcha), composição corporal 
(índice de massa corporal)] e a QV (Minnesota Living With Heart Failure 
Questionnaire).	A atividade física foi avaliada pela versão curta do IPAQ e por 
acelerómetros (ActiGraph GTX3).	No Estudo III, utilizamos o modelo animal de 
ratos obeso ZSF1.	Os animais foram divididos aleatoriamente em um grupo de 
 XXII 
exercício ou sedentário.	No final do protocolo, todos os animais foram 
submetidos ao teste de tolerância ao esforço e à avaliação hemodinâmica 
invasiva.	Após o sacrifício, amostras de sangue e do VE foram coletadas para 
análise.		
Resultados:	No Estudo I, nossos dados sugerem que o equilíbrio dinâmico e 
mobilidade é a componente da aptidão física que melhor se associa à QV em 
pacientes com ICFEP.	No Estudo II, nossos dados sugerem que a versão curta 
do IPAQ subestima o tempo sedentário e sobrestima a AF de intensidade 
moderada-vigorosa (AFMV).	Além disso, diariamente os pacientes passam 
reduzido tempo em AFMV, que foi a única categoria de intensidade de AF 
associada positivamente a indicadores prognósticos.	Finalmente, no Estudo III, 
mostramos que exercício físico crônico melhorou a capacidade de exercício, 
atenuou a rigidez do VE e reduziu os níveis circulantes de citocinas inflamatórias 
e marcadores de disfunção endotelial e estresse oxidativo, em ratos com ICFEP.		
Conclusões:	Os resultados sugerem que a aptidão física, particularmente o 
equilíbrio dinâmico e a mobilidade, deve ser um alvo da avaliação de pacientes 
com ICFEP por se relacionar com a QV.	Além disso, os dados da AF auto 
reportados podem ser inapropriados para o aconselhamento e prescrição 
adequada de alterações do estilo de vida.	Em relação aos hábitos de AF, nossos 
dados revelam a importância de incentivar os doentes com ICEFP a aumentarem 
os níveis de AFMV.	Finalmente, o exercício físico parece ter um impacto positivo 
na rigidez do VE através da modulação das propriedades intrínsecas dos 
cardiomiócitos e da remodelagem da matriz extracelular.	
 
Palavras-chave:	Aptidão física, atividade física, exercício físico, insuficiência 
cardíaca com fração de ejeção preservada, qualidade de vida, capacidade 
funcional, função diastólica.	
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ABSTRACT 
 
Rational: Heart failure with preserved ejection fraction (HFpEF) continues to be 
refractory to available therapies, with current treatment guidelines highlighting the 
importance of focusing on the improvement of patient’s well-being or other health-
related outcomes. There is also an increasing awareness of the need for novel 
approaches not only for the treatment of HFpEF but also for its prevention through 
the early identification and management of potential modifiable contributing risk 
factors. Physical fitness or physical activity (PA) are becoming recognized as key 
modifiable factors for the prevention of HFpEF and management of cardinal 
symptoms such as exercise intolerance and quality of life (QoL). From a clinical 
perspective, physical fitness and PA may be considered important targets if we 
aim to maximize the health care of these patients. However, there are some gaps 
in this field that may challenge the effectiveness of physical fitness and PA based-
interventions. First, because physical fitness is a multicomponent construct, it is 
important to understand how this syndrome affects the different components, and 
which of them is better representative of health-related outcomes. Second, in 
order to provide tailored counselling and prescription to HFpEF patients, it is 
crucial that the instruments that we use to measure PA levels are accurate and 
reliable. While the use of questionnaires may be easy to apply in the clinical 
practice, it remains to be confirmed if self-reported and objectively measured PA 
is correlated in HFpEF. Third, while there is some evidence that exercise training 
can improve diastolic function in HFpEF patients, the mechanisms underlying 
these changes remain poorly comprehend.  
Purpose: In the current work, we propose to: i) study the association between 
different components of physical fitness and the dimensions of QoL in HFpEF 
patients; ii) examine which of the physical fitness components are independently 
related to different dimensions of QoL; iii) to determine the validity of the 
International Physical Activity Questionnaire (IPAQ) against objective measures 
from accelerometry in HFpEF patients; iv) to describe the patterns of daily PA 
and sedentary time and assess which is better associated with prognostic 
indicators; v) evaluate the effects of exercise training on LV function and 
structure, and underlying molecular changes, using the ZFF1 obese animal 
model of HFpEF.  
Methods: In order to accomplish the proposed aims, we evaluated 24 HFpEF 
patients (Study I and II). Patients were assessed for physical fitness [dynamic 
balance and mobility (8-feet-up-and go test), upper body strength (handgrip 
strength), cardiorespiratory fitness (CRF) (6-minute-walking test), body 
composition (body mass index)] and for QoL (Minnesota Living With Heart Failure 
Questionnaire). Physical activity was assessed through the IPAQ short version 
and triaxial accelerometry (ActiGraph GTX3). In order to evaluate the effects of 
exercise training on LV function and structure, and underlying molecular changes 
(Study III), we used the ZSF1 obese animal model. Animals were randomly 
divided in a training or sedentary group. At the end of the protocol, all animals 
were submitted to exercise tolerance test, and invasive hemodynamic evaluation. 
After sacrifice, blood and left ventricular samples were collected for analysis.  
 XXIV 
Results: In Study I, our data suggests that dynamic balance and mobility is the 
only physical fitness component that better capture QoL in HFpEF patients. In 
Study II, our data suggests that the IPAQ short version underestimates sedentary 
time and over-estimates MVPA. In addition, patients spent only a minority of their 
time involved in moderate-to-vigorous PA, which was the only PA pattern 
positively associated with prognostic indicators. Finally, in Study III, we show that 
chronic exercise training improved exercise capacity, attenuated LV stiffness and 
reduced circulating levels of inflammatory cytokines and markers of endothelial 
dysfunction and oxidative stress in rats with HFpEF.  
Conclusions: Our data suggests that physical fitness, particularly dynamic 
balance and mobility, should be evaluated in HFpEF patients, once that it is 
associated with QoL. Also, physical activity data gathered solely by self-reported 
instruments may lead biased counselling and prescription. Regarding to PA 
patterns, our data points for the importance of recommending HFpEF to more 
engaged in MVPA. Finally, exercise training seems to positively impact left 
ventricular stiffness by modulating both cardiomyocyte’s intrinsic proprieties and 
extracellular matrix remodelling.  
 
Keywords: Physical fitness, physical activity, exercise training, heart failure with 
preserved ejection fraction, quality of life, functional capacity, diastolic function. 
  
 XXV 
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1. OVERVIEW OF HEART FAILURE 
Heart failure (HF) is a clinical syndrome caused by impaired cardiac 
structure and/or function, resulting in a reduced cardiac output and/or elevated 
intracardiac pressures at rest or during stress, which leads to exercise intolerance 
(Ponikowski et al., 2016). It affects approximately 26 million people worldwide, 
and accounts for an estimated annual health care cost of $31 billion (Mozaffarian 
et al., 2016). In Portugal, the EPICA study reported a prevalence of HF ranging 
from 7.6% in the 60–69-year-old group to 16.1% in patients >80 years (Ceia et 
al., 2002). In addition, it is estimated that the prevalence of HF in Portugal will 
increase by around 7% in 2018, 30% in 2035 and 33% in 2060 (Fonseca et al., 
2018). Despite the evident progresses in the treatment of cardiovascular disease 
over the past decades, the incidence and prevalence of HF have not decreased, 
survival has slightly improved, and morbidity remains excessively high (Meta-
analysis Global Group in Chronic Heart Failure, 2012). One of the challenges and 
barriers in successfully treating HF is the phenotypic heterogeneity found on this 
condition (e.g. different pathophysiology, disease severity and response to 
therapy) (Abbate et al., 2015). 
Heart failure is usually associated with reduced left ventricular ejection 
fraction (LVEF) (HFrEF), but it is now recognized that HF also encompasses a 
wide range of patients with normal LVEF, defined as HF with preserved ejection 
fraction (HFpEF) (Ponikowski et al., 2016). Heart failure with preserved ejection 
fraction represents approximately 50% of patients with HF, and it is the main form 
of HF in adults aged above 65 years old (Dunlay et al., 2017). It is estimated that 
by 2020, the relative prevalence of HFpEF and HFrEF are predicted to reach 69% 
and 31%, respectively (Steinberg et al., 2012). Patients with HFpEF exhibit a 
long-term prognosis similar to HFrEF, with a five-year survival of less than 50% 
(Shah et al., 2017). In addition, while there are a few pharmacologic and non-
pharmacological therapies demonstrated to improve survival and reduce HF 
hospitalization in HFrEF, the scenario is less satisfactory for patients with HFpEF 
as, up to date, no recognized therapies have shown important reductions in 
morbidity or mortality (Nanayakkara et al., 2018). 
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Given the increasing prevalence of HFpEF, there is an urgent need of 
clinical and translational research to better characterize this population and to 
identify effective strategies for the prevention and management of HFpEF. 
 
2. HEART FAILURE WITH PRESERVED EJECTION FRACTION 
2.1. Definition and diagnosis criterion 
Heart failure with preserved ejection fraction is a clinical syndrome 
characterized by normal ejection fraction at the expense of increased left 
ventricular filling pressures (Andersson & Vasan, 2014). 
 The diagnosis of HFpEF remains defiant, once that signs and symptoms 
are often non-specific and do not help to distinguish between HF and other clinical 
conditions presenting similar manifestations such as in obese individuals, in the 
elderly and in patients with chronic lung disease (Ponikowski et al., 2016). Typical 
symptoms of HF are breathlessness, ankle swelling, fatigue and reduced 
exercise tolerance, which may be accompanied by signs such as elevated jugular 
venous pressure, pulmonary crackles and peripheral oedema (Ponikowski et al., 
2016). Patients are usually classified into subgroups based on exercise limitation 
and their symptoms using the New York Heart Association (NYHA) functional 
class. Functional capacity is classified with objective assessment (class A to D), 
while patient’s symptoms are based on how much they are limited during physical 
activity (class I to IV) (Dolgin, 1994). 
 According to current European Society of Cardiology (ESC) 
recommendations (Ponikowski et al., 2016), the diagnosis of HFpEF requires the 
following conditions to be fulfilled: i) signs and/or symptoms of HF (mentioned 
above); ii) preserved ejection fraction (defined as LVEF >50%); iii) elevated levels 
of natriuretic peptides (BNP >35 pg/mL and/or N-terminal pro B-type natriuretic 
peptide (NT-proBNP) >125 pg/mL); and objective evidence of other cardiac 
functional and structural alterations underlying HF. Finally, in case of uncertainty, 
a stress test or invasively measured elevated left ventricle (LV) filling pressure 
may be needed to confirm the diagnosis. 
Key structural alterations include a left atrial volume index (LAVI) >34 mL/m2 
or a left ventricular mass index (LVMI) ≥115 g/m2 for males and ≥95 g/m2 for 
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females. Key functional alterations are an E/e′ ≥13 (ratio of early transmitral 
diastolic flow velocity to tissue Doppler early mitral annular diastolic velocity) and 
a mean e’ septal and lateral wall <9 cm/s (Ponikowski et al., 2016). A summary 
of the diagnostic criteria for HFpEF according to ESC recommendations is 
presented in Table 1. 
 
Table 1: Diagnostic criteria for HFpEF according to ESC guidelines. 
History and examination Symptoms and signs of HF 
Ejection fraction ≥50 
Natriuretic peptides BNP>35 pg/mL and/or 
NT-proBNP> 125pg/mL 
Imaging Cardiac structural alterations 
LAVI >34 mL/m2 
LVMI ≥115 g/m2 (males) ≥95 g/m2 (female) 
And/or cardiac functional alterations 
E/e’ mean septal-lateral ≥13 
Mean e’ septal/lateral wall <9 cm/s 
Additional indirect measures 
Reduced global longitudinal strain 
Elevated PASP (from TR velocity) 
ECG AF, LVH, repolarization abnormalities 
Exclusions Exclude other known causes of HF 
Further testing in case of 
uncertainty 
Diastolic stress test 
E/e’, PASP, strain, SV and CO 
or invasive assessment of LV pressures 
Rest PCWP ≥15mmHg(≥25mmHg with 
exercise) or LVEDP ≥16mmHg±change with 
exercise* 
Adapted from (Zakeri & Cowie, 2018). AF: atrial fibrillation; BNP: b-type natriuretic peptide; CO: 
cardiac output; HF: heart failure; HFpEF: heart failure with preserved ejection fraction; LAVI: left 
atrial volume index; LV: left ventricular; LVEDP: left ventricular end diastolic pressure; LVH: left 
ventricular hypertrophy; LVMI: left ventricular mass index; NT-proBNP: N-terminal pro B-type 
natriuretic peptide; PASP: pulmonary artery systolic pressure; PCWP: pulmonary capillary wedge 
pressure; SV: stroke volume; TR: tricuspid regurgitation. 
 
2.2. Epidemiology  
The prevalence of HFpEF ranges from 1.1% to 5.5% and represent 40%-
70% of HF cases (Oren & Goldberg, 2017). In Portugal, it is estimated that 
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126.898 patients will be suffering from HFpEF in 2018 (Fonseca et al., 2018). 
The prevalence of HFpEF is expected to increase mainly because of the rise in 
global life expectancy, significant advances in diagnosis, and high exposure to 
risk factors (Dunlay et al., 2017). Patients with HFpEF are more likely to be 
women and old aged, with a higher prevalence of cardiovascular comorbidities 
(e.g. hypertension, atrial fibrillation and valvular disease) (Dunlay et al., 2017) 
and non-cardiovascular comorbidities (e.g. anaemia, chronic kidney disease and 
cancer) (Lund et al., 2014). 
Outcomes following hospitalization for decompensated HFpEF are quite 
poor, with a mortality rate of 5.9% at 30 days and 33% after 1 year (Ziaeian et al., 
2017). In-hospitalization mortality rate was estimated to range from 1.6% to 5.1% 
(Goyal et al., 2016). Regarding all-cause mortality, according to data from 
randomized controlled trials (RCT), it can range from 13% to 23% over a mean 
follow-up period of 26-50 months (Vaduganathan et al., 2016). The main causes 
of death in HFpEF patients often varies according to the study setting. Results 
from a meta-analysis suggest that cardiovascular causes are the predominant 
mode of death in HFpEF, especially from sudden death and worsening of HF 
(MAGGIC, 2012). However, as opposed to HFrEF, non-cardiovascular deaths 
also account for a significant proportion of deaths, with some data suggesting 
that they may even represent the most prevailing cause of mortality in HFpEF 
patients (Vaduganathan et al., 2017). 
 
2.3. Risk Factors  
The understanding of the contributing role of each risk factor implicated in 
the development of HFpEF is a hard task, once there is a wide inter-individual 
variation, and their possible interactions can also modulate the chances of 
developing HFpEF (Andersson & Vasan, 2014). Overall, the most important risk 
factors for the development of HFpEF include advanced age, female gender, and 
physical inactivity (Ponikowski et al., 2016). In addition, cardiovascular risk 
factors are found to be highly prevalent in HFpEF in population-based studies 
and registries, which include overweight/obesity (83%) (Haass et al., 2011), 
hypertension (60-80%) (Dunlay et al., 2017), coronary arterial disease (20-76%) 
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(Lam et al., 2011), diabetes mellitus (20-45%) (Dunlay et al., 2017), and atrial 
fibrillation (15–41%) (Fonarow et al., 2007; Olsson et al., 2006). In addition, the 
presence of non-cardiovascular comorbidities is highly prevalent in HFpEF 
patients, likely contributing to poor outcomes. Non-cardiovascular comorbidities 
include renal dysfunction, chronic obstructive pulmonary disease, anaemia, 
cancer, liver disease, peptic ulcer disease, among others (Ather et al., 2012). 
 
2.4. Pathophysiology  
As illustrated in Figure 1, HFpEF is caused by a complex interaction of 
multiple impairments in parallel with diastolic dysfunction and ventricular stiffness 
(Fontes-Carvalho & Leite-Moreira, 2011; Zakeri & Cowie, 2018). It is frequently 
associated with impairments in ventricular systolic reserve function, heart rate 
reserve and rhythm, atrial and renal dysfunction, vascular stiffness, endothelial 
dysfunction, impaired vasodilatation, pulmonary hypertension, and peripheral 
alterations, such as abnormalities of skeletal muscle (Borlaug, 2014; Fontes-
Carvalho & Leite-Moreira, 2011; Oren & Goldberg, 2017; Zakeri & Cowie, 2018). 
Patients with HFpEF are most often characterized at the cardiac level by a 
non-dilated LV, concentric LV hypertrophy or concentric LV remodelling, and 
diastolic dysfunction (Oren & Goldberg, 2017). The maladaptive ventricular 
hypertrophy of the LV is associated with an increase in myocardium stiffness due 
to the increased interstitial fibrosis (van Heerebeek et al., 2012) and changes in 
the expression and level of phosphorylation of cytoskeletal proteins (Castro-
Ferreira et al., 2011; Hamdani et al., 2013). This leads to functional changes that 
manifest as incomplete myocardial relaxation and increased filling pressures of 
the LV (Chaturvedi et al., 2010; Ferreira-Martins & Leite-Moreira, 2010; van 
Heerebeek et al., 2012). In addition, other contributing factors were identified 
such as LV systolic dysfunction (Kraigher-Krainer et al., 2014), right ventricular 
dysfunction (Guazzi et al., 2011), chronotropic incompetence (Brubaker et al., 
2006), autonomic deregulation (Borlaug et al., 2006), impaired vascular 
(Schwartzenberg et al., 2012), pulmonary and renal functions (Maurer et al., 
2007), and impaired skeletal muscle function (Haykowsky et al., 2013). 
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Figure 1: Complex interaction of multiple impairments associated with the heart 
failure with preserved ejection fraction syndrome. Central mechanisms comprise LV 
diastolic and systolic stiffening and dysfunction, RV dysfunction, atrial fibrillation and left 
atrial dysfunction. Peripheral mechanisms comprise impaired pulmonary and renal 
function, arterial stiffness, abnormalities of skeletal muscle and endothelial dysfunction. 
AF: atrial fibrillation; LA: left atrial; LV: left ventricular; RV: right ventricular. Adapted from 
(Zakeri & Cowie, 2018). 
  
 The mechanisms underlying HFpEF remain poorly understood. A new 
paradigm was recently proposed to explain HFpEF (Paulus & Tschope, 2013). 
According to this hypothesizes, low-grade chronic systemic inflammation derived 
from comorbidities is responsible for coronary microvascular inflammation, which 
leads to myocardial dysfunction and remodelling (Figure 2). Coronary 
microvascular endothelial cells produce reactive oxygen species (ROS), which 
limits nitric oxide (NO) bioavailability for adjacent cardiomyocytes, leading to a 
downregulation of endothelium-cardiomyocyte signalling [cyclic guanosine 
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monophosphate content (cGMP) and protein kinase G (PKG) activity] which 
promotes myocardial hypertrophy and cardiomyocyte stiffness (Franssen et al., 
2016). In addition, the increased expression of cell adhesion molecules promotes 
subendothelial infiltration of circulating monocytes. Monocytes release 
transforming growth factor β (TFG- β), which promote the differentiation of 
fibroblasts into myofibroblasts, thus increasing interstitial collagen deposition and 
interstitial fibrosis. Increased cardiomyocyte stiffness and interstitial fibrosis 
induce diastolic LV dysfunction (Paulus & Tschope, 2013). 
 
 
 
Figure 2: Impact of systemic inflammation on the pathogenesis of HFpEF. 
Exposure to comorbidities promotes a low-grade systemic pro-inflammatory state that, 
when sustained, will disturb the coronary microvascular endothelium through the 
increased production of reactive oxygen species and increased expression of cell 
adhesion molecules (CAMs). The dysfunctional endothelium affects the signalling from 
the endothelium to adjacent cardiomyocytes [reduced cyclic guanosine monophosphate 
content (cGMP) and protein kinase G (PKG) activity] which promotes cardiomyocytes 
hypertrophy and increase resting tension because of hypophosphorylation of titin. On 
the other hand, the CAMs promote the infiltration of monocytes, releasing transforming 
growth factor β (TGF-ß), which promote the differentiation of fibroblasts into 
myofibroblasts, thus increasing interstitial collagen deposition. Overall, increased 
hypertrophy, cardiomyocyte resting tension and fibrosis will account for cardiac stiffness. 
IL-6: interleukin-6; CRP: C-reactive protein; TNF-α: tumor necrosis factor alfa; NO: nitric 
oxide; sGC: soluble guanylate cyclase; ICAM: intercellular adhesion molecules; VCAM: 
vascular cell adhesion molecules. 
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2.5. Treatment  
According to 2016 ESC guidelines, no therapy has been consistently proven 
to reduce morbidity or mortality in patients with HFpEF (Ponikowski et al., 2016). 
However, since these patients are often elders, highly symptomatic, and 
perceiving a poor quality of life (Fukuta et al., 2016), current treatment ESC 
guidelines highlight the importance of aiming to alleviate symptoms and improve 
patients well-being (Ponikowski et al., 2016). Patients should be screened for 
cardiovascular and non-cardiovascular comorbidities, which if present, should be 
managed with interventions that have been shown to improve symptoms, well-
being or other health-related outcomes, without exacerbating HF (Ponikowski et 
al., 2016). 
Because HFpEF continues to be refractory to available therapies, there is 
an urgent need for novel approaches not only for the treatment and management 
of HFpEF but also for its prevention. Indeed, some authors are now arguing that 
the attention needs to be directed to the early steps of this syndrome, by the 
screening and management of the potential modifiable contributing factors, 
ultimately to prevent HFpEF (Bobenko et al., 2018; Kondamudi et al., 2017). In 
this sense, growing body of evidence is also highlighting the value of physical 
activity (PA)/exercise training programs in the prevention of HFpEF and in the 
management of cardinal symptoms such as exercise intolerance and quality of 
life (Chan et al., 2016). Indeed, the current ESC guidelines highlight the 
importance of PA/exercise training to HFpEF management (Ponikowski et al., 
2016). 
 
3. THE ROLE OF PHYSICAL ACTIVITY IN HFPEF 
3.1. Definition of physical activity and sedentary time  
Physical activity is usually defined as any body movement produced by 
skeletal muscles that require energy expenditure (Caspersen et al., 1985). It is 
commonly categorized according to four different contexts: occupational, 
household, transport and leisure-time or recreational PA (Physical Activity 
Guidelines Advisory Committee Scientific Report, 2018). In addition, PA can be 
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classified by its intensity, such as light [1.5-3 metabolic equivalents (METs)], 
moderate (3-6 METs), and vigorous or very vigorous intensity (≥6METs) (Riebe 
et al., 2018). By comparison, exercise training is defined as a sub-component of 
PA that is characterized to be a deliberated practice, planned, structured, and 
repetitive, and is designed with the specific purpose of improving or maintaining 
physical fitness, physical performance, or health (Caspersen et al., 1985). 
Regarding sedentary time, it is defined as any waking activity characterized by a 
low level of energy expenditure (≤1.5 METs) while sitting, reclining, or lying 
(Tremblay et al., 2017). 
 
3.2. Measurement of physical activity and sedentary time 
As PA is a multidimensional practice, valid measurements in free-living 
individuals can be a challenging task, regardless the population. There are 
several methods for measuring PA, and each one has its own particular 
limitations and strengths. These methods include subjective (e.g. questionnaire) 
and objective instruments (e.g. accelerometer). Questionnaires are a simple 
instrument, easily-administered, appropriate to use in large samples for research 
purposes, and is cost-effective (Besson et al., 2010). In addition, it allows 
identifying the context in which PA is performed (e.g. occupational and leisure-
time or recreational) (Besson et al., 2010). However, the assessment of PA by 
questionnaires is based on self-reports, and therefore, most often biased due to 
social desirability, inaccurate memory, and the inability to capture the absolute 
level of PA intensity (Prince et al., 2008). Accelerometers are motion sensors 
specially designed to assess PA and related energy expenditure. Measurements 
with accelerometers provide accurate and reliable information about total PA, as 
well as about the intensities and time spent at each PA intensity in everyday life 
activities (Cheung et al., 2011; Gorman et al., 2014). Furthermore, the device size 
is small and easy to wear. Unfortunately, accelerometers are expensive and 
challenging because of the large volume of data that generate and/or the required 
expertise to the data management, which make it difficult to use in large 
epidemiologic studies (Troiano, 2005). 
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Sedentary behaviour or sedentary time can also be ascertained from PA 
questionnaires or accelerometry, respectively. Lower sedentary time is usually 
related to higher levels of PA in many individuals, however, these variables are 
not necessarily correlated. In fact, it is somewhat common to find individuals who 
perform higher levels of PA but, concomitantly, also accumulate higher levels of 
sedentary time (e.g. sedentary job) (Thorp et al., 2011). 
 
3.3. Physical activity in the prevention of HFpEF 
Several studies are supporting the notion that to control the growing burden 
of HFpEF, we have to change the focus for primary prevention and identify 
modifiable risk factors that can be targeted. Lifestyle risk factors, such as low PA, 
sedentary time, and low cardiorespiratory fitness (CRF) are becoming 
increasingly recognized as major risk factors for most chronic diseases, including 
HF (Booth et al., 2012; Djousse et al., 2009; Kenchaiah et al., 2009). Indeed, a 
number of community-based studies have demonstrated an inverse association 
between PA levels and risk of HF. The Women’s Health Initiative, an 
observational study with a cohort of 84.537 participants, demonstrated that a 
relatively high levels of PA was associated with decreased HF risk (Agha et al., 
2014). Similar results were found in a prospective cohort study using data from 
20.900 men, where adherence to healthy lifestyle factors was associated with a 
lower lifetime risk of HF (Djousse et al., 2009). In addition, physical inactivity 
(defined as not meeting the recommended amount of health-related PA within a 
week) was also related to increased risk for HF (He et al., 2001). Young and 
colleagues examined the correlation between PA and prolonged sedentary time 
on risk of HF in 82.695 men followed for 10 years (Young et al., 2014). The 
investigators found that apart from higher PA, lower sedentary time was 
associated with reduced risk of HF incidence, and these associations had 
independent contributions (Young et al., 2014).  
While it remains to be clarified which HF phenotype is the mostly affected, 
some reports suggest that PA and sedentary time may be more strongly 
implicated in the development of HFpEF than in HFrEF. A recent study with a 
pooled analysis from three large cohorts demonstrated an inverse relationship 
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between leisure-time PA and HF risk, where lower levels of PA were associated 
with higher risk of HFpEF but not HFrEF (Pandey et al., 2017). Additionally, in an 
elderly cohort from the Framingham Heart Study, lower PA levels were more 
strongly associated with risk of HFpEF (Kraigher-Krainer et al., 2013). 
Furthermore, corroborating this notion of HF phenotype specificity, it was shown 
a strong dose-dependent inverse association between lifetime doses of exercise 
training and LV compliance and distensibility, which are hallmark features of 
HFpEF (Bhella et al., 2014). Finally, there is evidence that sedentary lifestyle 
(prolonged bed rest) is also associated with many of the underlying cardiac and 
skeletal muscle abnormalities often present in HFpEF (Dorfman et al., 2008; 
Irimia et al., 2017). Thus, it seems that PA and/or sedentary time are important 
modifiable aspects to be targeted to prevent HFpEF. In addition to that major key 
point, it needs to be highlighted that the above-mentioned studies support their 
conclusions on questionnaire-derived information, which often overestimate PA 
(Lee et al., 2011), and thus do not allow to extract precise data for PA 
prescription. To overcome this important limitation, objectively measures of PA, 
such as those derived from accelerometry, need to be explored. Because the use 
of accelerometers in large cohort studies is not feasible, an alternative approach 
may be the evaluation of physical fitness since it can be relatively easily assessed 
and is strongly related to PA. Recent work from the Cooper Centre Longitudinal 
Study showed that in midlife, lower CRF, which is one component of physical 
fitness, is more powerfully associated with a marked increase in the risk for HF 
than acute myocardial infarction in older age (Berry et al., 2013). In addition, lower 
CRF in midlife was related to a larger degree of diastolic dysfunction and LV 
remodelling, important hallmarks of HFpEF (Brinker et al., 2014). Similar risk 
patterns were recently observed by Pandey and co-workers, where lower CRF in 
young adulthood was strongly associated with subclinical diastolic filling 
impairment 20 years later (Pandey et al., 2017a). Finally, CRF was inversely 
associated with relative wall thickness and LVMi in adults, both hallmarks of 
HFpEF (Lam et al., 2010). Collectively, these studies suggest that higher levels 
of PA, less time spent in sedentary behaviours and a greater CRF are strongly 
associated with a reduced risk of HFpEF. 
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3.4. Physical activity in the management of HFpEF  
The role of PA/exercise training programs on the management of HFpEF is 
gaining special attention, with published data suggesting their benefits on several 
clinical outcomes with important prognostic implication. In the next section, we 
will review the main findings regarding outcomes as hospitalization and mortality, 
exercise capacity, quality of life, cardiac function and remodelling, and 
biochemical markers of biological processes include in HFpEF.  
 
3.4.1. Hospitalization and mortality 
A dose-response relationship between PA levels and risk of adverse 
outcomes, such as HF hospitalization, have been well described in patients with 
HFrEF (Sagar et al., 2015). However, the impact of increasing PA levels in those 
with HFpEF is less clear. Recent evidence from the TOPCAT study, with a cohort 
of 1.751 individuals, showed that higher levels of PA among stable patients with 
HFpEF were associated with a reduced risk of adverse outcomes, including 
hospitalization and cardiovascular mortality (Hegde et al., 2017). The reduced 
risk of adverse outcomes may be related to better indices of diastolic function, as 
previously noted in other cohort studies with 2.925 individuals (Brinker et al., 
2014). It is important to note that in the TOPCAT study, the authors observed a 
dose-response relationship between PA levels and risk of adverse clinical 
outcomes, such that only PA levels at or above current recommended guidelines 
(150 min/week of moderate activity, or at least 75 min/week of vigorous activity, 
or 150 min/week of a combination of both) were associated with a lower risk of 
hospitalization or mortality (Hegde et al., 2017). These data suggest that a higher 
dose of PA may be required to achieve benefits regarding hospitalization and/ 
mortality. However, since the TOPCAT study relied on PA measurements by 
questionnaire, it should be viewed with wariness. For a better understanding of 
the impact of PA in HF hospitalization and mortality, a more objective method for 
PA quantification, such as PA actigraphy using accelerometers, should be used. 
Regarding structured exercise training, while RCTs support its safety (Chan et 
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al., 2016), the effect on mortality or hospitalization is largely unknown and future 
studies need to specifically address these endpoints. 
 
3.4.2. Exercise capacity 
Several studies demonstrated significant improvements in exercise capacity 
with PA and exercise training interventions in patients with HFpEF. A multicentre 
study from the NEAT-HFpEF trial evaluated daily PA levels using accelerometers 
in 110 patients with HFpEF (Snipelisky et al., 2017). The authors reported a 
significant association between PA levels and exercise capacity assessed 
through the 6-minute walk test (6MWT), where patients with lower levels of daily 
PA had lower exercise tolerance. This was corroborated in the multicentre ALDO-
DHF trial with 442 ambulatory HFpEF patients, where the total amount of PA 
(METs/week) was positively correlated with submaximal exercise capacity 
(Bobenko et al., 2018). Indeed, HFpEF patients have a significant reduction in 
exercise capacity (Dhakal et al., 2015), which can lead to early fatigue and 
reduction in the overall volume of daily activity. In comparison with healthy 
individuals at risk of HF, and HFrEF patients, it seems that patients with HFpEF 
have the lower volume of objectively measured daily PA (Yavari et al., 2017).  
Moreover, a positive effect of exercise training on exercise capacity was 
also shown by a meta-analysis addressing large HFpEF trials (Chan et al., 2016). 
From the 8 studies included in the final analysis, 5 showed a significant 
improvement in peak oxygen consumption (VO2peak) (+2.08 ml.kg-1.min-1; 15% 
increase), which is above the clinically meaningful change (1 ml.kg-1.min-1 or 
10%) in VO2peak for patients with HF (Kitzman, 2011). In addition, 4 studies 
reported a significant increase in walking distance on the 6MWT (+32.1 meters). 
Of note, these improvements were obtained with different types of exercise. Just 
to mention some, Haykowsky and colleagues performed 4 months of endurance 
exercise training in HFpEF patients and found an improvement of 2.3 ml.kg-1.min-
1 on VO2 peak (Haykowsky et al., 2012). In addition, a multicentre RCT compared 
3 months of combined endurance and strength training with usual care alone in 
64 clinically stable patients with HFPEF. Peak VO2 increased with exercise 
training (from 16.1±4.9 ml.kg-1.min-1 to 18.7±5.4 ml.kg-1.min-1; p<0.001), while it 
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remained unchanged with usual care alone (Edelmann et al., 2011). Finally, 
aerobic interval training was also effective to significantly improve VO2 peak in 
HFpEF patients (Fu et al., 2016) as well as to improve exercise tolerance above 
the threshold considered clinically relevant (Alves et al., 2012). Interestingly, a 
recent meta-analysis showed that the single use of standard cardiovascular 
medications failed to improve exercise capacity, while its combination with 
exercise training was effective to increase VO2 peak and the performance in 
6MWT (Fukuta et al., 2016).  
The physiological mechanisms underlying these improvements in exercise 
capacity in HFpEF patients are poorly comprehended. Poor exercise response 
was shown to be due to a reduction in both cardiac output and arteriovenous 
oxygen content difference (Houstis et al., 2018). Therefore, by knowing the 
effects of exercise training in other clinical settings, it seems logical to 
hypothesize that training would improve exercise capacity by influencing both 
factors. However, current data supports that the greater VO2peak found in HFpEF 
patients after training is paralleled by an increase in oxygen extraction but not by 
cardiac output (Fu et al., 2016; Haykowsky et al., 2012). Nevertheless, it needs 
to be highlighted that the number of studies assessing cardiac hemodynamic 
after training is very low and the number of recruited patients is reduced (Fu et 
al., 2016; Haykowsky et al., 2012). Moreover, these studies were not designed to 
test the most effective dose to potentially improve hemodynamic factors, and it 
may be the case that cardiac responsiveness to training is reduced and requires 
prolonged (several months to years) and/or more intensity of training programs 
as recently suggested for healthy seniors (Bhella et al., 2014). Indeed, it was 
shown that competitive master athletes demonstrated improved ventricular 
compliance (lower LV chamber stiffness constants) and distensibility (greater 
LVEDVi) compared to that in casual exercisers and sedentary subjects (Bhella et 
al., 2014). Finally, because HFpEF patients are so heterogeneous, it may be the 
case that the magnitude of responsiveness of each factor to training is dependent 
on the patient’s personal profile of defects (Houstis et al., 2018). Figure 3 
summarizes how these factors could cooperate to improve exercise capacity in 
HFpEF. 
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Figure 3: Potential mechanisms by which exercise training might improve VO2peak 
in HFpEF. Current evidences suggest that an increase in oxygen extraction but not in 
cardiac output is the main responsible for improved VO2 peak. Dotted grey line means 
that there is no evidence of improved cardiac output in HFpEF patients. However, only 
2 studies with a small number of patients assessed cardiac hemodynamic. More 
evidences are needing to better understand the contribute of both factors.  
 
3.4.3. Quality of life 
Health-related quality of life has been considered another very important 
outcome for HFpEF patients. Higher levels of PA were related with better quality 
of life measured by the Kansas City Cardiomyopathy Questionnaire (Hegde et 
al., 2017; Snipelisky et al., 2017). Regarding to exercise training, most of the 
studies assessed quality of life by the Minnesota Living with Heart Failure 
Questionnaire (MLHFQ) (Rector & Cohn, 1992). This questionnaire was 
developed to assess the patient’s perception of the impact of the disease and its 
treatment on their life, and it reflects the general, physical and the emotional 
dimensions of quality of life. In a recent meta-analysis, Chan and colleagues 
evaluated the effects of exercise training on quality of life in 317 participants with 
HFpEF (174 exercising and 143 control) (Chan et al., 2016). The authors reported 
that 7 out of 8 studies showed significant improvements in general MLHFQ score 
(mean difference of -6.77 points). Nevertheless, the authors did not perform any 
analysis by each dimension (emotional and/or physical). However, it seems that 
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the large majority of the studies using the MLHFQ (and reporting the dimensions) 
showed an improvement only in the physical dimension of quality of life 
(Edelmann et al., 2011; Kitzman et al., 2010). This may be explained by the 
attenuating effect of exercise training over exercise intolerance and fatigue, 
increasing patients’ ability to cope with the demands of daily tasks, and 
consequently improving the perceived quality of life in the physical dimension (Fu 
et al., 2016). Finally, Smart et al. (2007) showed that 16 weeks of exercise 
training only significantly improved the emotional dimension in HFpEF patients 
(Smart et al., 2007). Taken together, these evidences suggest that exercise 
training programs are effective strategies to induce positive effects on general 
quality of life.  
 
3.4.4. Cardiac function and remodelling  
Despite the overall beneficial effects of increasing levels of PA in HFpEF 
patients, it remains poorly understood if it can also modulate cardiac function and 
remodeling. Some preliminary clues to this aspect are provided by a recent study 
showing that HFpEF patients engaged in lower levels of daily PA (objectively 
measured by accelerometry) presented higher NT-proBNP levels, more 
concentric left ventricular remodeling (higher relative wall thickness), larger LAVi, 
and a tendency to have higher E/e′ (Snipelisky et al., 2017). Contrasting findings 
where shown by Bobenko and collogues, who did not found association between 
E/e´ or LAVi and PA levels in HFpEF patients. However, since in the last study 
PA levels were based on self-report, the results should be viewed with wariness 
(Bobenko et al., 2018).       
 Regarding to the impact of exercise training on diastolic function in HFpEF, 
early meta-analysis suggested that exercise training was not associated with 
significant changes in diastolic function (Pandey et al., 2015). This lack of 
evidence could be due to the different standard measures of diastolic function 
(E/A ratio and deceleration time) between studies included in the meta-analysis. 
Moreover, the E/e’ is considered a more specific non-invasive indicator of 
diastolic function, once that it is a less load dependent index of LV relaxation and 
less influenced by heart rate or age (Pearson et al., 2017). However, studies 
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using this parameter were scarce at that time (n=1) and thus were exclude from 
meta-analysis. In this sense, a more recent meta-analysis of 8 studies, with 317 
participants, showed that exercise training programs significantly improve 
diastolic function (changes on E/e’, E/A and/or deceleration time) (Chan et al., 
2016). These results differ from the meta-analysis aforementioned because it 
included more studies that evaluated E/e’. Future studies using invasive 
assessment (catheterization) of cardiovascular properties at rest and during 
exercise may provide a more sensitive analysis of alterations induced by exercise 
training (Borlaug & Kass, 2009). In the meantime, improvement of diastolic 
function with exercise training was also demonstrated in pre-clinical studies 
(Hidalgo et al., 2014; Slater et al., 2017). 
Regarding the underlying mechanisms, so far, the literature does not 
elucidate how exercise training could improve diastolic function in HFpEF 
patients. Edelmann and colleagues demonstrated that exercise training improves 
LV diastolic function and atrial reverse remodelling without change in LV mass, 
suggesting a switch from pathologic into a more physiologic hypertrophy 
(Edelmann et al., 2011). Indeed, exercise training has the ability to 
counterbalance the structural and functional cardiac changes induced by 
cardiovascular diseases, contributing to phenotypical changes of pathological 
cardiac hypertrophy into physiological cardiac hypertrophy (Fernandes et al., 
2015). In addition, exercise training was associated with a significant reduction in 
procollagen type I plasma levels, suggesting that improvement in diastolic 
function may be associated with reduced collagen turnover (Edelmann et al., 
2011). NT-proBNP is the gold standard marker for myocyte stress and the 
decreases in NT-proBNP levels were associated with reduced mortality and 
morbidity rates in HFpEF patients (Anand et al., 2011). While exercise training 
was capable to significantly reduce the circulating concentrations of NT-proBNP 
(Conraads et al., 2004) or BNP (Nakanishi et al., 2017) in HFrEF patients, no 
significant changes have been noted in patients with HFpEF (Edelmann et al., 
2011; Kitzman et al., 2010). However, it is important to highlight that levels of 
NTproBNP (Edelmann et al., 2011) or BPN (Kitzman et al., 2010) in these studies 
were below the levels that were reported in acutely decompensated HFpEF. 
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Finally, whether exercise training can modulate LV compliance and distensibility 
in HFpEF remains to be explored, but these diastolic variables were recently 
shown to be modulated by exercise training in healthy middle age individuals 
(Howden et al., 2018) and in healthy seniors (Bhella et al., 2014). 
Further insights of the molecular mechanisms underlying exercise-induced 
benefits in HFpEF are provided by animal models. Pre-clinical studies of HFpEF 
suggest that exercise-induced improvement on diastolic function are linked to 
decreased myocardial stiffness (Figure 4). A recent work evaluated the effect of 
free-wheel running exercise on cardiac stiffness (extracellular matrix and titin-
based stiffness) in a genetic mouse model (TtnΔIAjxn), where the I-A junction of 
titin is removed resulting in increased diastolic stiffness and reduced exercise 
tolerance (Slater et al., 2017). The data revealed that intrinsic myocardial 
stiffness was reduced in the running group, which was associated with reduced 
titin-based passive stiffness in a phosphorylation-dependent manner, as no effect 
was detected on extracellular matrix (Slater et al., 2017). The authors observed 
that the reduction in passive stiffness was mainly related to both decreased PEVK 
phosphorylation and increased N2B phosphorylation (Slater et al., 2017). The 
phosphorylation of PEVK element by protein kinase Cα (PKCα) increases titin 
stiffness, while phosphorylation of N2B element by protein kinase A (PKA) or 
protein kinase G (PKG), decreases titin stiffness (Kotter et al., 2013). Voluntary 
exercise in genetically engineered mice with HFpEF symptoms (IG KO mice), 
was shown to decrease PKCα expression level in the LV, lowering titin-based 
stiffness and improving diastolic filling (Hidalgo et al., 2014). In addition, Slater 
and colleagues reported that voluntary exercise in TtnΔIAjxn mice increases titin 
phosphorylation by PKA, leading to diminished titin stiffness and improved 
diastolic function (Slater et al., 2017). These studies suggest that reduced 
passive tension induced by exercise appears to be explained mainly by 
modification of cardiac titin phosphorylation status, rather than by titin isoform 
expression. Indeed, these experimental studies did not found changes in the ratio 
of the N2B or N2BA titin isoforms (Hidalgo, Saripalli, & Granzier, 2014; Slater et 
al., 2017). 
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At the level of extracellular matrix, treadmill exercise training was shown to 
attenuate diastolic impairment by reducing fibrosis in the Yucatan miniature swine 
model of HFpEF (aortic-banded to produce concentric LV hypertrophy) (Marshall 
et al., 2013). The reduction of fibrosis was associated with normalization in the 
relative mRNA levels of matrix metalloproteinases (MMPs) (MMP-2 and MMP-9), 
and their tissue inhibitors (TIMPs) (TIMP-1 and TIMP-4). Modification on the 
collagen degradation system was shown to be an important contributor to 
alterations on extracellular matrix, which can lead to diastolic dysfunction 
(Westermann et al., 2011).  
While the upstream modulators of this beneficial effects are also far from 
being comprehended, it can be hypothesized that the systemic effects promoted 
by exercise training may interfere with the cascade of events leading to cardiac 
stiffness and HF development. Indeed, previous data from different clinical 
conditions provides evidence that exercise training has anti-inflammatory (Smart 
& Steele, 2011) and anti-oxidative proprieties (Sties et al., 2018) and improves 
endothelial function (Pearson & Smart, 2017), all of which are thought to be 
implicated in the pathophysiology of HFpEF (Paulus & Tschope, 2013). 
Despite these molecular insights provided by pre-clinical studies, it is 
important to highlight that none of these animal models fully mimic the spectrum 
of changes found in humans with HFpEF. In addition, in humans, HFpEF is a 
condition typically associated to underlying comorbidities and exercise 
intolerance, while development of these conditions is rather rare in most animal 
models (Lourenco et al., 2018). In an attempt to surpass these limitations, a new 
HFpEF model using the obese ZSF1 rat has been proposed (Hamdani et al., 
2013). It is considered a robust model as these animals display hypertension, 
obesity, type 2 diabetes, insulin resistance, hyperinsulinemia, 
hypertriglyceridemia and hypercholesterolaemia (Hamdani et al., 2013). Over 
time, this cardiometabolic risk model develops the main features found in humans 
diagnosed with HFpEF: i) reduced exercise tolerance and VO2peak, ii) preserved 
systolic function (LVEF, LV maximum rate of pressure rise, and the slope of linear 
end-systolic pressure-volume relationship for indexed volumes) and iii) diastolic 
dysfunction (higher E/e’, increased left atrial area, prolonged tau, elevated left 
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ventricular end-diastolic pressure, an upwards shift of LV diastolic pressure-
volume relationship, and higher LV diastolic chamber stiffness constant) 
(Hamdani et al., 2013; Leite et al., 2015). 
 
Figure 4: Effects of exercise training on myocardial stiffness. Exercise training can 
reduce titin-based passive stiffness and LV fibrosis. It is related with decrease protein 
kinase (PK) Cα (PKCα) expression and increases PKA, which leads to both decreased 
PEVK phosphorylation and increased N2B phosphorylation, respectively. Reduced 
fibrosis may be mediated by normalization in the relative mRNA levels of matrix 
metalloproteinases (MMPs) and their tissue inhibitors (TIMPs), reducing the producing 
of collagen. ONOO: peroxynitrite, NO: nitric oxide, sGC: soluble guanylate cyclase; 
GMP: guanosine monophosphate content; ICAM: intercellular adhesion molecules; 
VCAM: vascular cell adhesion molecules. 
 
4. PHYSICAL ACTIVITY/EXERCISE PRESCRIPTION FOR MANAGEMENT 
OF HFPEF 
The optimal dose of PA that is beneficial to improve adverse outcomes in 
HFpEF patients is unknown. The current American Collage of Sport and Medicine 
(ACSM) PA guidelines recommend for older adults a minimum of 150 min/week 
of moderate activity, or at least 75 min/week of vigorous activity, or 150 min/week 
of moderate plus vigorous activity, to promote health and reduce the risk of 
chronic disease (Physical Activity Guidelines Advisory Committee Scientific 
Report, 2018). However, the current guidelines were not specifically tailored to 
patients with established HFpEF. It is recognized that there is an inverse dose-
response relationship between PA and health-related benefits (Hegde et al., 
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2017). Indeed, recent findings shown that only the highest PA intensities 
measured by accelerometers were associated with maximal exercise capacity 
(Bobenko et al., 2018). However, as Yavari and colleagues observed, for the 
majority of patients with HFpEF it is difficult to achieve the minimum 
recommended amount of moderate or vigorous PA per week (Yavari et al., 2017). 
In this sense, it is important to highlight that the ACSM PA guidelines make clear 
that any increase in the amount of PA, regardless the intensity, translates into 
health benefits (Physical Activity Guidelines Advisory Committee Scientific 
Report, 2018). In the clinical context, patients should be encouraged to increase 
the daily total time spent at moderate or vigorous PA and progressively increase 
the frequency and duration at this intensity. 
Regarding exercise training, although ESC guidelines recommend that 
HFpEF patients should perform properly designed exercise training (Ponikowski 
et al., 2016), there is no specific recommendations regarding the type, doses or 
intensity of exercise that can be followed to optimize the management these 
patients. While this work was not designed to systematically review the literature 
in order to be able to suggest which is the most effective exercise training 
program, it seems that the type of exercise is an important “ingredient” to 
positively modulate the main clinical outcomes in HFpEF. In fact, combined 
endurance and resistance training for 3 months (2-3 days/week) (Edelmann et 
al., 2011), as well 6 months (2–3/week) (Nolte et al., 2014) were shown to 
improved functional capacity, quality of life and diastolic function in HFpEF 
patients. In addition, aerobic interval training performed 3 times per week for 12 
weeks (Fu et al., 2016) or 6 months (Alves et al., 2012) was also able to improve 
functional capacity and diastolic function. Quality of life was also improved by the 
former cited study (Fu et al., 2016). Conversely, moderate aerobic exercise 
training, performed 3 times per week for 16 weeks (Haykowsky et al., 2012; 
Kitzman et al., 2010; Smart et al., 2012) or 1 year (Fujimoto et al., 2012) was not 
effective to improve diastolic function in HFpEF patients. In addition, inspiratory 
muscle training for 12 weeks was able to improve exercise capacity and quality 
of life, but no changes on diastolic function was observed (Palau et al., 2014). In 
summary, combined exercise training or aerobic interval training seems to be the 
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better type of exercise to improve exercise capacity, quality of life and diastolic 
function in HFpEF. These types of exercise training may be particularly important 
for older age or frail patients who may not be able to tolerate continuous aerobic 
exercise. Three times per week, for 12 weeks was shown to be sufficient to 
induce these benefits. However, the necessary amount of exercise training to 
maintain these benefits is unknown. 
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CHAPTER II 
 
 
GAPS AND AIMS  
 
  
CRISTINE SCHMIDT | HEART FAILURE WITH PRESERVED EJECTION FRACTION: FROM PROGNOSIS TO CARDIAC FUNTION | 
 
38 
  
  
CRISTINE SCHMIDT | HEART FAILURE WITH PRESERVED EJECTION FRACTION: FROM PROGNOSIS TO CARDIAC FUNTION | 
 
39 
From the above brief review, some gaps in the literature were identified, 
which leverage the original studies encompassing this thesis. First, previous 
evidence shows that lower levels of physical fitness are associated with poor 
quality of life in patients with HFpEF (Kitzman et al., 2010; Nolte et al., 2015), but, 
up to date, only CRF was associated with a better quality of life, specifically with 
the physical dimension (Edelmann et al., 2011; Kitzman et al., 2010). However, 
physical fitness is multicomponent construct (e.g. dynamic balance and mobility, 
muscular fitness, CRF and body composition) (Rikli & Jones, 2013) and quality 
of life is multidimensional (e.g. general, emotional and physical) (The World 
Health Organization Quality of Life Assessment Group, 1998). Therefore, it 
remains unknown whether other physical fitness components impact on 
dimensions of quality of life, in HFpEF patients. Better clarification of this issue 
might have important clinical implications in the design of specific interventional 
programs for HFpEF patients by targeting the physical fitness component that 
mostly impacts quality of life. Therefore, the first aim of the thesis was: 
 
STUDY 1:  
a) to examine the association between different components of 
physical fitness (CRF, upper body strength, dynamic balance 
and mobility, and body composition) and the dimensions of 
quality of life (total, physical and emotional) in HFpEF patients; 
b) to examine which of the physical fitness components are 
independently related to different dimensions of quality of life in 
this specific population. 
 
Second, in HFpEF patients there is a lack of studies describing and 
comparing daily PA levels assessed by questionnaire and accelerometers. There 
is a growing recognition of the important role that PA can have on the 
management of HFpEF (Hegde et al., 2017). From a clinical point of view 
accurate and reliable methods to assess PA are needed to provide tailored 
counselling and prescription. Therefore, the second aim of the thesis was: 
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STUDY 2:  
a) to determine the validity of the International Physical Activity 
Questionnaire (IPAQ) against objective measures from triaxial 
accelerometry in HFpEF patients;  
b) to describe patterns of daily PA and sedentary time measured by 
accelerometry; 
c) to study the association of objective PA measures with 
prognostic indicators. 
 
Third, although there is some evidence that exercise training can improve 
diastolic function in HFpEF patients, the mechanisms underlying this 
improvement are still unknown. In the impossibility to obtain human cardiac 
biopsies, pre-clinical models are the preferred choice to address this issue. 
However, given the complex pathophysiology underlying HFpEF, none of the 
current models fully mimic the human phenotype. The ZSF1 obese animal model 
was shown to present several features of HFpEF (Hamdani et al., 2013; Leite et 
al., 2015), placing this model one step ahead towards clinical translation 
(Lourenco et al., 2018). However, to our best knowledge, there are no studies 
evaluating the impact of exercise training in HFpEF using this model. 
Understanding the exercise-induced adaptations may hold promise as potential 
targets and open the door to novel therapeutic approaches aimed at restoring 
diastolic function. Therefore, the third aim of the thesis was: 
 
STUDY 3:  
a) to examine the effects of exercise training on diastolic function in 
the ZSF1 obese animal model of HFpEF; 
b) to analyse structural and molecular changes induced by exercise 
training.  
 
To accomplish the first and second aims, a cross-sectional study with 
HFpEF patients was conducted in a Portuguese public hospital (Centro 
Hospitalar do Porto - Hospital de Santo Antonio, Porto). Patients were recruited 
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from November 2016 to September 2017. All data from each patient was collated 
in the same day. The obtained data are presented in Study I and Study II in the 
next section. To accomplish the third aim, a low-intensity exercise training 
protocol using the ZSF1 obese animal model was conducted, which gave origin 
to our Study III. 
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STUDY I 
 
DYNAMIC BALANCE AND MOBILITY EXPLAINS QUALITY OF LIFE IN HEART 
FAILURE WITH PRESERVED EJECTION FRACTION, OUTPERFORMING ALL 
THE OTHER COMPONENTS OF PHYSICAL FITNESS  
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ABSTRACT 
 
Rational: Physical fitness is an important determinant of quality of life (QoL) in 
heart failure with preserved ejection fraction (HFpEF) patients. However, physical 
fitness and QoL are multicomponent and multidimensional, respectively, 
remaining unknown how the different components of physical fitness relate with 
the specific dimensions of QoL in HFpEF patients. 
Aim: To evaluate the association between different components of physical 
fitness and dimensions of QoL in HFpEF patients, and, to examine which physical 
fitness components are independently related to different dimensions of QoL. 
Methods: Patients with HFpEF (n=24; stable and well-medicated) were recruited 
and assessed for physical fitness [dynamic balance and mobility (8-feet-up-and 
go test), upper body strength (handgrip strength), cardiorespiratory fitness (CRF) 
(6-minute-walking test) and body composition (body mass index)] and for QoL 
(Minnesota Living With Heart Failure Questionnaire). The dimensions of QoL 
were total score, emotional and physical. Partial correlation was used to verify 
the association between physical fitness components and dimensions of QoL. 
The determination of independent predictors dimensions of QoL was computed 
through stepwise multivariate linear regression analysis.  
Results: Both CRF and dynamic balance and mobility are significantly 
associated with total score and physical dimensions of QoL (p<0.05), but only 
dynamic balance and mobility was concomitantly associated with the emotional 
dimension (r=0.597; p=0.004). Dynamic balance and mobility was independently 
associated with total score (b=0.651; r2=0.424; p=0.001), physical (b=0.570; 
r2=0.324; p=0.04) and emotional (b=0.611; r2=0.373 p=0.002) dimensions of 
QoL. Upper body strength, CRF, body composition were not independent 
predictors of any dimensions of QoL (p>0.05). 
Conclusion: Our data suggests that dynamic balance and mobility better capture 
QoL than the commonly measured in clinical practice CRF. Whether interventions 
specifically targeting dynamic balance and mobility differently impacts on QoL is 
still unknown.  
 
Keywords: physical fitness, quality of life, dynamic balance and mobility, HFpEF.  
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INTRODUTION 
Heart failure with preserved ejection fraction (HFpEF) accounts for half of 
all HF population in the developed world (Dunlay et al., 2017). The most common 
manifestation of the disease is exercise intolerance, which impacts on patients’ 
ability to cope with activities of daily life and reduces their quality of life (QoL) 
(Edelmann et al., 2011b). Furthermore, QoL is related with poor outcomes such 
as higher frequency of hospital readmission and higher mortality rates 
(Rodriguez-Artalejo et al., 2005). Despite its high prevalence and poor prognosis, 
HFpEF remains a disease with no approved therapy that improves survival 
(Holland et al., 2011). Therefore, current recommendations for the treatment of 
these patients highlight the importance to focus on effective therapies capable to 
alleviate symptoms and meaningfully improve QoL (Ponikowski et al., 2016). 
Reduced levels of physical fitness are associated with poor QoL in patients 
with HFpEF (Kitzman et al., 2010; Nolte et al., 2015). Importantly, exercise 
training was shown to improve physical fitness, together with an amelioration in 
symptoms and QoL (Kitzman et al., 2010; Nolte et al., 2015). Because physical 
fitness and QoL are mutually related, targeting physical fitness with exercise 
training programs may be an effective strategy to accomplish the management 
recommendations of patients with HFpEF (Ponikowski et al., 2016). However, 
physical fitness is multicomponent construct (e.g. dynamic balance and mobility, 
muscular fitness, cardiorespiratory fitness (CRF) and body composition) (Rikli & 
Jones, 2013) and, in parallel, QoL is multidimensional (e.g. general, emotional 
and physical) (The World Health Organization Quality of Life Assessment Group, 
1998). Until now, it remains unknown how the different components of physical 
fitness relate with the specific dimensions of QoL in HFpEF patients. To date, it 
was only demonstrated that higher CRF is associated with a better QoL, mainly 
the physical dimension (Edelmann et al., 2011a; Kitzman et al., 2010). However, 
the influence of other physical fitness components on QoL dimensions is 
relatively unknown. Therefore, the clarification of this issue might have important 
clinical implications in the design of specific interventional programs for HFpEF 
patients targeting the physical fitness component that most impacts QoL in 
general or in one of its depressed dimensions. 
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Therefore, the aims of the present study are twofold: i) to evaluate the 
association between different components of physical fitness (CRP, upper body 
strength, dynamic balance and mobility, and body composition) and the 
dimensions of QoL (total, physical and emotional) in HFpEF patients, and ii) to 
examine which of the physical fitness components are independently related to 
different dimensions of QoL in this specific population. 
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MATERIAL AND METHODS 
 
Study design, recruitment and participants  
This is a cross-sectional study conducted in a Portuguese public hospital 
(Centro Hospitalar do Porto - Hospital de Santo Antonio, Porto). Inclusion criteria 
was diagnosis of HFpEF according to the European Society of Cardiology 
guidelines (McMurray et al., 2012). Patients were excluded if they presented with 
unstable angina, acute coronary syndrome as primary diagnosis, symptomatic 
severe aortic stenosis, acute pulmonary embolus, acute myocarditis, 
uncompensated heart failure, uncontrolled hypertension, complex ventricular 
arrhythmias, severe renal dysfunction, severe chronic obstructive pulmonary 
disease, medical or orthopaedic conditions that precluded independent 
ambulation and exercise testing. 
Patients who potentially were eligible to participate in the study were 
identified from the clinical files of the hospital’s cardiology department. A total of 
30 patients were invited through phone calls by a cardiologist. From those, 24 
patients (17 women and 7 men) accepted to take part in the study. The study was 
approved by the Ethics Committee of Centro Hospitalar do Porto - Hospital de 
Santo Antonio (N/S: 2015.125). All procedures were conducted according to the 
declaration of Helsinki, and participants signed informed consent to participate 
Data were collected from November 2016 to September 2017 in a single 
day in the hospital. 
 
Data collection 
Blood pressure  
A trained researcher performed blood pressure measurements after 
10 minutes resting in seated position. Blood pressure was assessed (Colin, BP 
8 800; Critikron, Inc., USA) in the left arm and systolic blood pressure and 
diastolic blood pressure were computed as the average of 3 readings. Additional 
readings were performed when differences between readings exceeded 5 mmHg 
(Mancia et al., 2014).  
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Blood collection and biochemical determinations 
Peripheral venous blood (15 mL) was collected to EDTA tube. The EDTA 
tubes were immediately placed on ice and allowed to clot for 30 minutes before 
centrifugation for 15 minutes at 1000xg. The plasma was aliquoted and stored at 
-80ºC for biochemical analysis. Brain Natriuretic Peptide (BNP) was quantified in 
a certificated laboratory by chemiluminescent microparticle immunoassay 
(ARCHITECT BNP). 
 
Anthropometric and body composition measures  
Body height (cm) was measured standing upright against a stadiometer 
(Holtain Ltd., Crymmych, UK) (Lohman, 1988). Patients were bare or stocking 
feet. Weight (kg), body mass index (BMI; kg/m2), fat mass (%) and free fat mass 
(kg) were measured with patients lightly dressed, using an electronic segmental 
body composition analyser (Tanita, BC-418, Tokyo, Japan). Waist circumference 
(cm) was measured at the midpoint between the lowest rib and the iliac crest at 
the end of normal expiration (Riley et al., 2016). Obesity was determined as BMI 
equal or higher than 30 kg/m2 (WHO, 2000). 
 
Functional classification 
Patients were classified by the physician into subgroups based on their 
symptoms using the New York Heart Association (NYHA) functional class. 
Patients symptoms is based on how much they are limited during physical activity 
(class I to IV) (Dolgin, 1994). 
 
Echocardiography Evaluation  
Supine transthoracic echocardiography was performed using a 
cardiovascular ultrasound Vivid E95 ® (GE Healthcare). All quantitative 
echocardiographic measurements were performed by a single reader blinded to 
the results of the other evaluations, using a computerized off-line analysis station. 
Peak early diastolic tissue velocity was measured at the septal and lateral mitral 
annulus. Mitral inflow velocity was assessed by pulsed wave Doppler from the 
apical 4-chamber view, positioning the sample volume at the tip of the mitral 
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leaflets. E/e’ ratio was calculated as E wave divided by e’ velocities. LV mass 
was estimated from LV linear dimensions and indexed to body surface area as 
recommended by ESC guidelines (Lang et al., 2015). LV hypertrophy was 
defined as LV mass indexed to body surface area (LVMi) >115 g/m2 in men or 
>95 g/m2 in women. LV volumes were estimated by the modified Simpson 
method using the apical 4- and 2-chamber views, and LVEF was derived from 
volumes in the standard manner. LA volume was estimated by the method of 
disks using apical 4- and 2-chamber views at an end-systolic frame preceding 
mitral valve opening and was indexed to body surface area to derive LA volume 
index. 
 
Physical Fitness 
Dynamic balance and mobility 
Dynamic balance and mobility was assessed with the 8-foot up and go 
(8FUG) test (Jones, 2002). Patient starts the evaluation in the seated position. 
After a signal, patient must stand up, walk 8 feet (2,44m), turned around a cone, 
and return back to the initial position as fast as possible (Jones, 2002). Patients 
had two attempts. Time (in seconds) to complete each trial was measured with a 
stopwatch and the result was the shorter trial (Jones, 2002). 
 
Upper body strength  
Grip strength (kg) was isometrically measured using a Lafayette Instrument 
Hand dynamometer (Model 78010, 78011, Indiana, USA). Both arms were 
measured 3 times while patients were seated, with shoulder adducted and 
neutrally rotated, the elbow flexed at 90°, and the forearm and wrist in neutral 
position. The average between attempts was used as final score for each arm 
(MacDermid et al., 2015). 
 
Cardiorespiratory fitness with pulmonary gas exchange assessment 
Cardiorespiratory fitness was assessed by the 6-minute walk test (6MWT) 
in a 25-m-long unobstructed corridor. Participants were instructed to walk the 
maximal distance in 6 minutes time. Resting stops were allowed when patients 
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feel to be necessary. The 6MWT was performed wearing a portable gas analyser 
(K4b2, Cosmed, Rome, Italy) and a heart rate monitor (Polar Electro Oy, 
Kempele, Finland). Oxygen uptake (VO2; mL.min-1.kg-1) and heart rate (HR; bpm) 
were measured directly and continuously. In addition, minute ventilation (VE; 
L.min-1), absolute and relative VO2, carbon dioxide output (VCO2; mL.min-1), 
ventilatory equivalents for oxygen (VE/VO2), ventilatory equivalents for carbon 
dioxide output (VE/VCO2) and respiratory gas exchange ratio (RER) were 
collected. Respiratory and HR samplings were collected in a breath-by-breath 
and beat-to-beat basis, respectively, and then, data were averaged over 5-s 
intervals. Data was calculated as the averaged of measures taken in test total 
duration (6 minutes). 
 
Health-related quality of life  
Health-related QoL was performed by interview through the Minnesota 
Living With Heart Failure Questionnaire (MLWHFQ). The MLHFQ encompasses 
21 questions, whose purpose is to determine how disease affects the physical, 
psychological and socioeconomic conditions of the patients during the previous 
month (Rector & Cohn, 1992). The questions compass symptoms and signs 
relevant to disease, levels of physical activity, work, social interaction, sexual 
activity, and emotions. The MLHFQ total score range from 0 to 105 (no 
impairment to maximum impairment). Two other scores can be determined: the 
physical dimension (8 items, 0–40), and the emotional dimension (5 items, 0–25). 
Higher MLHFQ score mean worse QoL. Answers options ranges from 0 (none) 
to 5 (very much), where 0 represented no limitation and 105 represented maximal 
limitation. 
 
Statistical analyses 
Data normality was verified by Shapiro Wilk test. Not normally distributed 
variables were transformed into natural logarithm (weight, fat mass, free fat mass, 
8FUG, MLHFQ total score, MLHFQ physical and MLHFQ emotional) for 
subsequent analysis and then transformed back to the original scale for the 
purpose of clarity. Data are expressed as mean ± standard deviation. Categorical 
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data are reported as absolute values and percentages. Between gender 
comparisons were performed by independent t-test and chi-square test as 
appropriated. Pearson’s correlation was used to analyse the relationship between 
physical fitness components (dynamic balance and mobility, upper body strength, 
CRF and BMI) to verify collinearity between variables (r>0.75). Partial correlation 
(adjusted for age, gender and NYHA class) was used to assess the association 
between physical fitness components and dimensions of QoL. Multivariate linear 
regression analysis, with stepwise selection of variables was performed to 
determine the relationship between QoL dimensions with age, gender, NYHA 
functional class and physical fitness components, that were identified as 
potentials independent predictors of QoL. Statistical analysis was performed 
using the IBM SPSS 24 software (SPSS, USA), and the statistical significance 
was set at p <0.05. 
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RESULTS 
 
Patient’s characteristics 
The demographic and clinical sings of patients are presented in Table 1. 
Patients’ mean age was 76±6 years old, ranging from 59 to 85 years, and 71% 
(n=17) were female. Overall, mean weight was 72±16 kg and % body fat was 
36±7%. Hypertension was the most prevalent comorbidity (n=22, 92%), followed 
by dyslipidemia (n=17, 71%) and obesity (n=14, 58%). Regarding NYHA 
functional class, 79% (n=19) of all patients were classified as class II. The BNP 
average was 288.9±191.5 pg/mL. Regarding cardiac function, mean ejection 
fraction was 60±6%, E/e′ ratio was 12.2±3.1, and 23% (n=6) of patients had 
E/e′>15. E/A ratio was 1.0±0.52. LAVI was 44.2 ±11.7 mL/m2, while 90% (n=22) 
of patients had LAVI >34 mL/m2, and LVMI was 231±95 g/m2. All patients had left 
ventricular hypertrophy. Comparisons between genders showed that male 
compared to female tended to be heavier (p=0.003), with more free fat mass 
(p<0.001) and exhibit higher waist circumference (p=0.04). Additionally, male 
compared to female (Table 1) had higher frequencies of being former smoker’s 
(p=0.001) and history of chronic obstructive pulmonary disease (p=0.021) 
compared to female (Table 1). 
 
Table 1: General patients characteristics (overall and by gender). 
 All 
(n=24) 
Women 
(n=17) 
Men 
(n=7) 
Sociodemographic characteristics     
Age (years) 76 ± 6.1 77 ± 6.2 74 ± 6 
Female (n) (%) 17 (71%) - - 
Anthropometrics      
Weight (kg) 72 ± 16 66 ± 10.2 86 ± 18.8* 
Body mass index (kg/m2) 31 ± 5 31 ± 5 32 ± 5 
Fat mass (%) 36 ± 7 38 ± 5 33 ± 8 
Free fat mass (kg) 45 ± 10 41 ± 5 57 ± 9* 
Trunk fat (%) 35% ± 6 33 ± 5 37 ± 9 
Waist circumference (cm) 101 ± 13 98 ± 10 109 ± 14* 
Risk factors, n (%)    
Obesity (BMI ≥ 30 kg/m2)  14 (58%) 9 (53%) 5 (72%) 
Former smoker  4 (17%) 0 4 (57%)* 
Hypertension  22 (92%) 15 (88%) 7 (100%) 
Dyslipidemia  17 (71%) 11 (65%) 6 (86%) 
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Type 2 diabetes  2 (8%) 1 (6%) 1 (14%) 
Pre-diabetic  9 (38%) 5 (29%) 4 (57%) 
Atrial fibrillation  12 (50%) 8 (47% 4 (57%) 
Atrial fibrillation (paroxysmal)  4 (17%) 3 (18%) 1 (14%) 
COPD  2 (8%) 0 2 (29%)* 
Obstructive sleep apnea  6 (25%) 2 (12%) 4 (57%) 
Clinical signs    
Resting HR (bpm) 72 ± 16 73 ± 16 73 ± 19 
SBP (mmHg) 136 ± 19 134 ± 18 142 ± 22 
DBP (mmHg) 70 ± 14 69 ± 15 74 ± 10 
BNP (pg/mL) 289 ± 192 272 ± 171 331 ± 224 
NYHA Functional class    
NYHA class I (%) 1 (4%) 0 1 (14%) 
NYHA class II (%) 19 (79%) 13 (77%) 6 (86%) 
NYHA class III (%) 4 (17%) 4 (24%) 0 
Medication, n (%)    
ACE-i/ARB  17 (71%) 12 (71%) 5 (72%) 
ß-Blocker  20 (83%) 14 (82%) 6 (86%) 
Loop diuretics  18 (75%) 11 (65%) 7 (100%) 
Statin  16 (67%) 11 (65%) 5 (72%) 
Digoxin  4 (17%) 3 (18%) 1 (14%) 
MRAs  2 (8%) 1 (6%) 1 (14%) 
Cardiac Function    
LVEF (%) 60 ± 6.3 61 ± 6 58 ± 6 
E/e´  12.2 ± 3.1 12.5 ± 3.2 11.6 ± 2.9 
E/A 1.0 ± 0.5 1.02 ±0.5 0.97 ± 0.5 
LVMI (gm/m2) 231 ± 95 203 ±61 279 ±126 
LAVI (mL/m2) 44.2 ± 11.7 44.8 ± 12.5 42.5 ±10.3 
BMI: body mass index; HR: heart rate; SBP: systolic blood pressure; DBP: diastolic blood 
pressure; NYHA: New York Heart Association; AF: atrial fibrillation; COPD: chronic obstructive 
pulmonary disease; ACEi/ARB: angiotensin-converting enzyme inhibitor and angiotensin receptor 
blocker; MRAs: mineralocorticoid receptor antagonists; EF: ejection fraction; E/e´: ratio of early 
mitral transmitral flow velocity with early diastolic velocity of the mitral valve annulus; E/A: mitral 
ratio of peak early to late diastolic filing velocity; LVMI: left ventricle mass index; LAVI: left atrium 
volume index. Data are mean ± SD. *p<0.05. 
 
Quality of life 
Table 2 shows results from MLHFQ. The score of total MLHFQ scale was 
26±24, whereas the physical and emotional MLHFQ subscales scores were 
12±13, and 5±7, respectively. No significant differences were found between 
women and men (p>0.05). 
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Table 2: Patients results from total score, physical and emotional dimensions of 
QoL. 
 Participants (n=24) Women (n=17) Men (n=7) 
Quality of life    
MLHFQ total score 26 ± 24 30 ± 26 14 ±12 
MLHFQ physical 12 ±13 15 ± 14 4 ± 4 
MLHFQ emotional 5 ± 7 6 ±7 3 ± 3 
MLHFQ: Minnesota Living With Heart Failure Questionnaire. Data are mean ± SD. 
 
Physical fitness 
Physical fitness results are presented in Table 3. Overall, 6MWT distance, 
8FUG and handgrip results were 10.9±3.6 seconds, 18.6±7.1kg, and 312±90 
meters, respectively. Comparisons between genders showed that male 
compared to female had higher grip strength (p<0.001). 
 
Table 3: Patient's results from physical fitness. 
  All (n=24) Women (n=17) Men (n=7) 
Physical Fitness 
dimensions 
     
Dynamic balance 
and mobility 
8FUG (s)  10.8 ± 3.6 11 ± 3.5 10.2 ± 4 
Upper body 
strength 
Handgrip (kg) 18.8 ± 7 15.6 ± 4.4 26.3 ± 6.3* 
CRF 
 
 
 
 
6MWT    
Distance (m) 312 ± 90 316 ± 91 301 ± 92 
VO2 (mL.min-1.kg-1) 11.2 ± 2.2 11 ± 2.2 11.6 ± 2.2 
VCO2 (mL.min-1) 728 ± 183 684 ± 157 836 ± 209 
VE (L.min-1) 28.6 ± 7.1 27.6 ± 7.3 31.2 ± 6.3 
VE/VO2 36.8 ± 7.81 38.8 ±8.3 32 ± 3.1* 
VE/VCO2 40 ± 5.69 40.7 ± 6.4 38 ±2.5 
RER  0.92 ± 0.11 0.90 ± 0.12 0.85 ± 0.09 
HR (bpm) 103 ± 33 100 ± 23 113 ± 33 
Body 
composition  
BMI (kg/m2) 31.1 ± 5.1 30.7 ± 5.4 32 ± 4.9 
CRF: cardiorespiratory fitness; 8FUG: eight-foot-up-and-go test; 6MWT: six-minute walk test; 
BMI: body mass index; VO2: oxygen uptake; VCO2:  carbon dioxide output; VE: minute ventilation; 
VE/VO2: ventilatory equivalents for oxygen; VE/VCO2: minute ventilation carbon dioxide output; 
RER: respiratory gas exchange ratio. Data are mean ± SD. *p<0.05. 
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Bivariate correlation between physical fitness components showed that the 
8FUG test was inverse correlated with handgrip (r=-0.47; p=0.01) and 6MWT 
distance (r=-0.81; p<0.001) (Table 4). 
 
Table 4: Bivariate correlation between physical fitness parameters.  
 Dynamic 
balance and 
mobility 
Upper body 
strength 
Cardiorespiratory 
fitness 
Body 
composition 
 8FUG Handgrip 6MWT BMI 
8FUG  -0.478* -0.816** -0.030 
Handgrip -0.478*  0.390 0.017 
6MWT -0.816** 0.390  -0.074 
BMI -0.030 0.017 -0.074  
8FUG: eight-foot-up-and-go test; 6MWT: six-minute walk test; BMI: body mass index. *p<0.05. 
**p>0.01. 
 
Association between physical fitness and quality of life  
Partial correlation between dimensions of QoL and physical fitness 
components are presented in Table 5. Better MLHFQ total score was directly 
correlated with 8FUG (r=0.563; p=0.008) and inversely correlated with 6MWT (r= 
-0.539; p=0.012). Regarding to MLHFQ physical, it was directly correlated with 
8FUG (r=0.529; p=0.014) and inversely correlated with 6MWT (r=-0.478 
p=0.028). Finally, MLHFQ emotional was directly correlated with 8FUG (r=0.597; 
p=0.004). 
 
Table 5: Partial correlation between dimensions of quality of life with physical 
fitness. 
 Dynamic 
balance and 
mobility 
Upper body 
strength 
Cardio-
respiratory 
fitness 
Body 
composition 
MLHFQ total  0.563* -0.118 -0.539* 0.208 
MLHFQ physical 0.529* -0.261 -0.478* 0.260 
MLHFQ emotional 0.597* -0.023 -0.394 0.199 
Adjusted for age, gender and NYHA functional class. 8FUG: eight-foot-up-and-go test; 6MWT: 
six-minute walk test; BMI: body mass index; MLHFQ: Minnesota Living with Heart Failure 
Questionnaire. *p<0.05.  
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Table 6 shows multivariate regression analysis for dimensions of QoL. All 
models were adjusted to age, gender and NHYA functional class as potential 
confounders. For MLHFQ total score, the 8FUG was the only parameter from 
physical fitness that remained an independent predictor (b=0.651; p=0.001) that 
explaining 42.4% of MLHFQ total score variance. The CRF was not an 
independent predictor of MLHFQ total score (p>0.05). Similarly, for MLHFQ 
physical dimension, the 8FUG was the single physical fitness component that 
remained as independent predictor (b=0.570; p=0.04) that explaining 32.4% of 
MLHFQ physical variance. The CRF was not an independent predictor of MLHFQ 
physical (p>0.05). Finally, for MLHFQ emotional, the 8FUG was the single 
physical fitness component that remained as independent predictor (b=0.611; 
p=0.002), explaining 37.3% of MLHFQ emotional variance. 
 
Table 6: Stepwise regression analysis assessing which physical fitness 
components were independently associated with specific dimension of quality of 
life. 
 b B R2 p 
MLHFQ total     
Ln 8FUG 0.651 5.015 0.424 0.001 
MLHFQ physical     
Ln 8FUG 0.570 3.788 0.324 0.040 
MLHFQ emotional     
Ln 8FUG 0.611 3.003 0.373 0.002 
Ln 8FUG: natural logarithm of eight-foot-up-and-go test; MLHFQ: Minnesota Living with Heart 
Failure Questionnaire; b: standardized regression coefficient; B: non-standardized regression 
coefficient; R2: adjusted coefficient of determination. 
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DISCUSSION  
The data provided by our study indicates that physical fitness is positively 
correlated with QoL in HFpEF patients. In addition, dynamic balance and mobility 
was the unique physical fitness component that was independently associated 
with QoL total score, and physical and emotional dimensions. These findings 
suggest that this specific component of physical fitness outperforms CRF in 
capturing HFpEF patients’ QoL. In addition, it highlights the need to study 
interventions targeting specifically these fitness components to enhance QoL 
gains. 
Despite the high prevalence and poor prognostic of HFpEF, evidence-
based therapies to convincingly reduce morbidity or mortality remains to be 
developed (Holland et al., 2011). These patients are often characterized by poor 
quality of life and current treatment guidelines highlight the importance of aiming 
to improve patients well-being (Ponikowski et al., 2016). Physical fitness is 
multicomponent construct (Rikli & Jones, 2013) and several studies shows it is a 
major determinant of QoL in HFpEF (Kitzman et al., 2010; Nolte et al., 2015). Our 
results corroborate this finding, once we observed that QoL total score strongly 
correlated with physical fitness (e.g. dynamic balance and mobility, and CRF) in 
HFpEF patients. 
Because physical fitness might influence QoL, strategies targeting physical 
fitness might potentially improve QoL, independently of further health benefits 
(Pandey et al., 2015). A recent meta-analysis showed that the combination of 
endurance exercise training together with cardiovascular drugs provide a 
clinically relevant improvement in both exercise capacity and QoL in HFpEF 
patients (Fukuta et al., 2016). However, physical fitness and QoL are 
multicomponent and multidimensional, respectively, and it is crucial to ascertain 
which dimension/component is better related to each other to maximize possible 
QoL improvements. 
Previous studies have shown that CRF is mainly associated with the 
physical dimension, but not necessarily with the total score or emotional 
dimension of QoL (Edelmann et al., 2011a; Kitzman et al., 2010). We observed 
that CRF (assessed by 6MWT) and dynamic balance and mobility (assessed by 
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8FUG) were both associated with physical dimensions of QoL. Moreover, 
dynamic balance and mobility was the only physical fitness component 
associated with emotional dimension of QoL, while upper body strength 
(assessed by handgrip) and body composition were not associated with any 
dimension. In addition, multivariate analysis revealed that the dynamic balance 
and mobility was the only physical fitness component independently associated 
with all dimensions of QoL, explaining 42% of variance in the total score QoL, 
32% of physical dimension and 37% of emotional dimension of QoL. Thus, of all 
the components of physical fitness, dynamic balance and mobility seems to be 
the one that better capture QoL in HFpEF patients. 
Collectively, our data suggest that improving the specific physical fitness 
component of dynamic balance and mobility, will eventually proportionate the 
greatest improvement in QoL. 8FUG reflects the specific demands of activities 
such as standing up from a seated position, walking short distances, turning, 
stopping and sitting down (Wall et al., 2000). This might be explained by the wide 
range of physical abilities, including lower body strength, dynamic balance, 
walking ability, agility and gait speed (Rikli & Jones, 2013) involved in the 8FUG. 
These abilities are also required in the normal daily tasks of an independent and 
autonomous life, especially in older people (Mlinac & Feng, 2016). Future studies 
(e.g. longitudinal training programs) should assess if an exercise training program 
focused on enhancing motor abilities (e.g. dynamic balance and mobility) will 
improve the physical and emotional components of QoL in HFpEF in comparison 
to current standard ones. 
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STUDY LIMITATIONS 
The small sample size and the cross-sectional design of our study limits the 
generalization of our results. Despite that, our sample gathers the usual clinical 
features of HFpEF population reported in large studies (Ponikowski et al., 2016) 
with higher prevalence of elderly women and higher prevalence of comorbidities. 
Further prospective cohort studies with a larger sample size are needed to 
strengthen or refute our conclusions that dynamic balance and mobility is more 
discriminative to capturing HFpEF patients' QoL. 
 
CONCLUSION 
Overall, our findings indicate that both CRF and dynamic balance and 
mobility are directly associated with total score and physical dimensions of QoL 
in patients with HFpEF, but only dynamic balance and mobility was concomitantly 
associated with the emotional dimension. Multivariate analyses revealed that 
dynamic balance and mobility outperforms CRF in capturing HFpEF patients' 
QoL.  
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STUDY II 
 
COMPARISON OF QUESTIONNAIRE AND ACCELEROMETER-BASED 
ASSESSMENTS OF PHYSICAL ACTIVITY IN PATIENTS WITH HEART 
FAILURE WITH PRESERVED EJECTION FRACTION: CLINICAL AND 
PROGNOSTIC IMPLICATIONS  
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ABSTRACT 
 
Rational: Heart failure with preserved ejection fraction (HFpEF) accounts for 
approximately 50% of heart failure cases and is associated with poor outcome. 
Higher physical activity (PA) levels are associated with greater quality of life and 
lower risk of hospitalization and mortality.  
Purpose: The study aims: i) to compare daily PA levels and sedentary time 
evaluated by the International Physical Activity Questionnaire (IPAQ) and by a 
triaxial accelerometer in HFpEF patients; ii) to describe daily PA patterns and 
sedentary time in HFpEF patients based in objective measurements; and iii) to 
observe the association between prognostic indicators and PA, and sedentary 
time measurements.  
Methods: This is a cross-sectional study with 24 stable and well-medicated 
HFpEF patients. Physical activity was assessed through the IPAQ short version 
and triaxial accelerometry (ActiGraph GTX3). Time spent in moderate-to-
vigorous PA (MVPA) from IPAQ was computed as self-reported walking and 
MVPA. MVPA from acceletrometry was set as ≥2752 counts/minute. Prognostic 
indicators were: distance on the 6-minute-walking test (6MWT), oxygen 
consumption (VO2) during the test, quality of life, brain natriuretic peptide plasma 
level, and E/e´ ratio.  
Results: Sample mean age was 76±4 years. Compared to accelerometry, IPAQ 
underestimated sedentary time (253±156 vs. 392±104 min/day, p=0.001) and 
overestimated MVPA (44±56 vs 19.3±26. min/day, p<0.001). Using IPAQ, 59% 
of patients met international PA by international guidelines, while using 
accelerometer-derived data, 27% of patients actually met the guidelines, 
decreasing to zero when considering the number of 10min-MVPA bouts. On 
average, accelerometer-derived data showed that HFpEF patients spent 50% 
(392±104 min/day) of their waking time in sedentary behaviours and 2.5% 
(19.3±26 min/day) in MVPA. Of measured surrogate prognostic markers, 
functional capacity (6MWT, r=0.652, p=0.04; VO2, r=0.512=, p=0.02) and quality 
of life (r=-0.490, p=0.04) were correlated with MVPA. 
Conclusion: The IPAQ short version underestimated sedentary time and over-
estimated MVPA in patients with HFpEF. Using accelerometer-derived data, 
HFpEF patients spent only a minority of their time involved in MVPA, which was 
the only PA pattern positively associated with prognostic indicators. Our results 
highlight the importance of replacing some time spent in sedentary activities by 
MVPA in HFpEF throughout the day. 
 
Key-words: physical activity, IPAQ, accelerometer, HFpEF, prognostic 
indicators.  
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INTRODUCTION 
Epidemiologic evidence indicates that heart failure (HF) prevalence has 
been increasing in the last decade, with heart failure with preserved ejection 
fraction (HFpEF) accounting up to half of HF population (Oktay et al., 2013). The 
growing prevalence of HFpEF is attributed to life-expectancy expansion, better 
diagnostic awareness therapy (Glezeva & Baugh, 2014), and increasing 
prevalence of major risk factors (e.g. obesity, diabetes, hypertension and atrial 
fibrillation) (Ather et al., 2012). Consequently, it is expected that HFpEF will 
become the most common cause of hospitalization in older adults over the 
coming years (Nanayakkara et al., 2018). Since HFpEF continues to be resistant 
to current therapies, primary prevention strategies might be useful to control its 
growing burden at the population level (Pandey et al., 2017a). Therefore, in 
addition to understanding the natural history and pathophysiology of HFpEF, it 
will be important to identify modifiable risk factors that can be targeted. 
Lifestyle risk factors such as low physical activity (PA) and high sedentary 
time are recognized as primary factors for most chronic diseases, including HF 
(Booth et al., 2012). While it remains to be clarified which HF phenotypes is most 
affected, recent observations have more strongly implicated low PA in the 
development of HFpEF (Pandey et al., 2017b). An inverse relationship between 
leisure-time PA and HF risk was recently demonstrate, where lower levels of PA 
were associated with higher risk of HFpEF, but not HF with reduced ejection 
fraction (Pandey et al., 2017). In addition, evidence shows that a sedentary 
lifestyle (e.g. prolonged bed rest) is associated with many underlying cardiac and 
skeletal muscle abnormalities often present in HFpEF (Dorfman et al., 2008; 
Irimia et al., 2017). For those with established HFpEF, lower levels PA have been 
associated with poor quality of life (QoL) and worse clinical outcomes such as 
functional class (NYHA) (Snipelisky et al., 2017), hospitalisation rate, and 
mortality (Hegde et al., 2017). Overall, these observational studies suggest that 
PA and/or sedentary time are important treatment targets to improve clinical 
outcomes in HFpEF. 
Regardless the population, daily PA assessment is a challenging task. 
There are different methods (e.g. self-report methods such as questionnaires or 
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objective methods such as accelerometry), and each one has its own limitations 
and strengths. Despite of it, accelerometry seems to be superior than 
questionnaires in terms of accuracy, reliability, representatively of daily activities 
and related energy expenditure (Skender et al., 2016). Additionally, in clinical 
settings (e.g. diagnosis, prognosis, or prescription of therapeutic interventions) 
accelerometry might represent a challenge compared to questionnaires, which 
are better in terms of costs and practicality. However, correlation between self-
report and objective PA measurements in the large majority of studies is poor 
(Lee et al., 2011). Additionally, there are no data comparing objective PA 
measurements (e.g. accelerometers) and questionnaire in HFpEF patients. 
Therefore, this study aimed: i) to determine the validity of the International 
Physical Activity Questionnaire (IPAQ) against objective measures from triaxial 
accelerometry in HFpEF patients; ii) to describe daily PA patterns and sedentary 
time in HFpEF patients based in objective measurements, and iii) to observe the 
association between prognostic indicators and PA and sedentary time 
measurements. 
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MATERIAL AND METHODS 
 
Study design, recruitment and participants  
This is a cross-sectional study conducted in a Portuguese public hospital 
(Centro Hospitalar do Porto - Hospital de Santo Antonio, Porto). Inclusion criteria 
was diagnosis of HFpEF according to the European Society of Cardiology 
guidelines (Ponikowski et al., 2016). Patients were excluded if they presented 
with unstable angina, acute coronary syndrome as primary diagnosis, 
symptomatic severe aortic stenosis, acute pulmonary embolus, acute 
myocarditis, uncompensated heart failure, uncontrolled hypertension, complex 
ventricular arrhythmias, severe renal dysfunction, severe chronic obstructive 
pulmonary disease, medical or orthopaedic conditions that precluded 
independent ambulation and exercise testing. 
Patients who potentially were eligible to participate in the study were 
identified from the clinical files of the hospital’s cardiology department. A total of 
30 patients were invited through phone calls by a cardiologist. From those, 24 
patients (17 female and 7 male) accepted to take part in the study, but only 22 
completed data acquisition. The study was approved by the Ethics Committee of 
Centro Hospitalar do Porto - Hospital de Santo Antonio (N/S: 2015.125). All 
procedures were conducted according to the declaration of Helsinki, and 
participants signed informed consent to participate. 
Data were collected from November 2016 to September 2017 in a single 
day in the hospital. 
 
Data collection 
Blood pressure  
A trained researcher performed blood pressure measurements after 
10 minutes resting in seated position. Blood pressure was assessed (Colin, BP 
8 800; Critikron, Inc., USA) in the left arm. Systolic blood pressure (SBP) and 
Diastolic blood pressure (DBP) were computed as the average of 3 readings. 
Additional measurements were performed when differences between readings 
exceeded 5 mmHg (Mancia et al., 2014).  
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Blood collection and biochemical determinations 
Peripheral venous blood (15 mL) was collected to EDTA tube. The EDTA 
tubes were immediately placed on ice and allowed to clot for 30 minutes before 
centrifugation for 15 minutes at 1000xg. The plasma was aliquoted and stored at 
-80ºC for biochemical analysis. Brain Natriuretic Peptide (BNP) was quantified in 
a certificated laboratory by chemiluminescent microparticle immunoassay 
(ARCHITECT BNP). 
 
Anthropometric Measures  
Body height (cm) was measured standing upright against a stadiometer 
(Holtain Ltd., Crymmych, UK) (Lohman, 1988). Patients were bare or stocking 
feet. Weight (kg), body mass index (BMI; kg/m2), fat mass (%) and free fat mass 
(kg) were measured with patients lightly dressed, using an electronic segmental 
body composition analyser (Tanita, BC-418, Tokyo, Japan). Waist circumference 
(cm) was measured at the midpoint between the lowest rib and the iliac crest at 
the end of normal expiration (Riley et al., 2016). Obesity was determined as BMI 
equal or higher than 30 kg/m2 (WHO, 2000). 
 
Self-Reported Physical Activity  
Self-reported physical activity was assessed with the short version of the 
International Physical Activity Questionnaire (IPAQ-SF) (Craig et al., 2003), 
through personal interview. The IPAQ contains seven items to estimate PA 
frequency and duration during the previous seven days. Additional questions on 
sedentariness were also asked. The IPAQ focus on vigorous and moderate 
physical activity intensities and walking periods lasting at least 10 minutes on 
week days. Additionally, the questionnaire asked about “sitting time” on week and 
weekend days. Frequency of activity was measured in days, and duration in 
hours and minutes. Total weekly PA was estimated using the instrument's scoring 
protocol by weighting time spent in each activity intensity with its estimated 
metabolic equivalent (MET) energy expenditure (Ipaq Research Committee, 
2005). IPAQ scoring protocol assigns the values of 3.3 METs to walking, 4.0 
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METs to moderate, and 8.0 METs vigorous activity (Ipaq Research Committee, 
2005). Meeting physical activity guidelines was defined as accumulating ≥150 
minutes per week of moderate-intensity physical activity (MVPA) (≥3 METs) 
(Haskell et al., 2007). Thus, to estimate MVPA data, we merged the reported 
activities ≥3 METs (walking + moderate + vigorous PA).  
 
Accelerometer-assessed physical activity 
Daily PA was measured using a triaxial accelerometer (Actigraph GT3X, 
Pensacola, FL, USA). The triaxial activity monitor measures acceleration in three 
individual orthogonal planes (vertical, antero-posterior and medio-lateral) and 
provides activity counts as a composite vector magnitude (VM) of these three 
axes (Sasaki et al., 2011). The VM is the square root of quadrate of the three 
separate dimensional axes [(x2+y2+z2)1/2] (Crouter et al., 2012). Participants were 
instructed to wear the accelerometer over the right hip for eight consecutive days, 
except while sleeping, bathing and water-based activities. The accelerometer 
was programmed to record triaxial data at a frequency of 30 Hz and 1 second 
length epochs. ActiLife software (Actigraph, Florida, USA, version 6.9) was used 
to process the accelerometer data. Data were downloaded and integrated into 
60-second epochs. Non-wear time was defined as 90 consecutive minutes of 
zero counts, with an allowance of 2-minutes of nonzero counts provided there 
were 30-minute consecutive zero count windows up and downstream (Choi et al., 
2011). Non-wear time was excluded from the analysis. Patients with valid data 
were those having a minimum of 4 days with at least 10 hours/day of wear-time. 
The output of the Actigraph was given in counts per minute (CPM) derived from 
VM. The average minutes/day spent at different categories of PA intensity was 
determined according to cut point that relate PA to counts/min: sedentary time 
(<200 counts/min) (Aguilar-Farias et al., 2014), light PA (LPA) (200-2751 
counts/min) and moderate and vigorous PA (MVPA) (>2752 counts/min) (Santos-
Lozano et al., 2013). Meeting international PA guidelines was defined as ≥150 
minutes/week of MVPA from accelerometry. This definition was applied 
considering: i) only MVPA that occurred in bouts of ≥10 minutes’ long (episodes 
of continuous MVPA lasting for at least 10 minutes) as specified by the guidelines 
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(Haskell et al., 2007), and ii) without bout length restriction (e.g. considering all 
MVPA including MVPA occurring in bouts shorter than 10 minutes’ duration). 
 
Functional classification 
Patients were classified by the physician into subgroups based on their 
symptoms using the New York Heart Association (NYHA) functional class. 
Patients symptoms is based on how much they are limited during physical activity 
(class I to IV) (Dolgin, 1994).  
 
Echocardiography Evaluation  
Supine transthoracic echocardiography was performed using a 
cardiovascular ultrasound Vivid E95 ® (GE Healthcare). All quantitative 
echocardiographic measurements were performed by a single reader blinded to 
the results of the other evaluations, using a computerized off-line analysis station. 
Peak early diastolic tissue velocity was measured at the septal and lateral mitral 
annulus. Mitral inflow velocity was assessed by pulsed wave Doppler from the 
apical 4-chamber view, positioning the sample volume at the tip of the mitral 
leaflets. E/e’ ratio was calculated as E wave divided by e’ velocities. LV mass 
was estimated from LV linear dimensions and indexed to body surface area as 
recommended by ESC guidelines (Lang et al., 2015). LV hypertrophy was 
defined as LV mass indexed to body surface area (LV mass index) >115 g/m2 in 
men or >95 g/m2 in women. LV volumes were estimated by the modified Simpson 
method using the apical 4- and 2-chamber views, and LVEF was derived from 
volumes in the standard manner. LA volume was estimated by the method of 
disks using apical 4- and 2-chamber views at an end-systolic frame preceding 
mitral valve opening and was indexed to body surface area to derive LA volume 
index. 
 
Cardiorespiratory fitness with pulmonary gas exchange analysis 
Cardiorespiratory fitness was assessed by the 6-minute walk test (6MWT) 
in a 25-m-long unobstructed corridor. Participants were instructed to walk the 
maximal distance in 6 minutes time. Resting stops were allowed when patients 
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feel to be necessary. The 6MWT was performed wearing a portable gas analyser 
(K4b2, Cosmed, Rome, Italy). Oxygen uptake (VO2; mL.min-1.kg-1) was measured 
directly and continuously. Respiratory samplings were collected in a breath-by-
breath, and then, data was averaged over 5-s intervals. Data was calculated as 
the averaged of measures taken in test total duration (6 minutes). 
 
Health-related quality of life 
Health-related QoL was performed by interview through the Minnesota 
Living With Heart Failure Questionnaire (MLWHFQ). The MLHFQ encompasses 
21 questions, whose purpose is to determine how disease affects the physical, 
psychological and socioeconomic conditions of the patients during the previous 
month (Rector & Cohn, 1992). The questions compass symptoms and signs 
relevant to disease, levels of PA, work, social interaction, sexual activity, and 
emotions. The MLHFQ total score range from 0 to 105 (no impairment to 
maximum impairment). Two other scores can be determined: the physical 
dimension (8 items, 0–40), and the emotional dimension (5 items, 0–25). Higher 
MLHFQ score mean worse QoL. Answers options ranges from 0 (none) to 5 (very 
much), where 0 represented no limitation and 105 represented maximal 
limitation. 
 
Statistical analyses 
Statistical analysis was performed using the IBM SPSS 24 software (SPSS, 
USA). Normal data distribution was examined by the Shapiro Wilk test. Non-
normal data was transformed with the square root (IPAQ-MVPA, 
IPAQ_METs/day, accelerometer-MVPA, accelerometer-10min-bouts-MVPA, 
MLHFQ total score, MLHFQ physical and MLHFQ emotional) or its natural 
logarithm (weight, fat mass, free fat mass, accelerometer total hours and 
accelerometer total days), for subsequent analysis and then transformed back to 
the original scale for the purpose of clarity. Categorical data are reported as 
absolute values and percentages. Between gender and age comparisons were 
performed by independent t-test and chi-square test as appropriated. Cut point 
to age analyses was defined by median, and it was set as 76 years old. Siting 
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time and walk+moderate+vigorous PA (MVPA) from IPAQ were compared with 
sedentary time, total MVPA and 10 min-bouts of MVPA derived from GT3X 
accelerometer, using paired t-test. Partial correlation was used to analyse the 
relationship between the variables derived from the two methods adjusted by 
gender and age. The strength and limits of agreement between the two methods 
was assessed using the Bland–Altman technique (Bland & Altman, 1986). 
Statistical significance was established for p <0.05.  
  
CRISTINE SCHMIDT | HEART FAILURE WITH PRESERVED EJECTION FRACTION: FROM PROGNOSIS TO CARDIAC FUNTION | 
 
81 
RESULTS 
 
Patients’ characteristics 
Demographic and clinical characteristics of the participants are depicted in 
Table 1. On average, participants were 76±4 years old (range 59-85 years), and 
73% (n=16) were female. For the whole sample, the mean weight was 71±16 kg 
and the % body fat was 36±6.6%. Hypertension was the most prevalent risk factor 
(n=20, 91%), followed by dyslipidaemia (n=15, 68%) and obesity (n=12, 55%). 
The majority of participants (n=17, 77%) were classified as NYHA class II. The 
BNP average was 272±191.56 g/mL. Regarding to cardiac function, mean 
ejection fraction was 59.4±6.3%, the E/e′ ratio was 12.2±3.1 and 32% of patients 
had E/e′>15. E/A ratio was 1.0±0.5, LAVI was 43±12 mL/m2 and LVMI 222±96 
gm/m2. All patients had left ventricular hypertrophy, and 95% of patients had LAVI 
>34 mL/m2. Regarding cardiorespiratory fitness, the mean distance walked in the 
6MWT was 312±90 meters. The average of VO2 during the test was 11.2 ±2.3 
ml.min.kg-1. The total score of MLWHFQ was 25.2 ± 24.1 points. 
Between genders comparisons showed that male compared to female 
tended to be heavier (p=0.004) and to have more free fat mass (p<0.001). 
Additionally, compared to female, male had higher frequencies of former smokers 
(p=0.002) as well as higher frequencies of chronic obstructive pulmonary disease 
(p=0.015) (Table 1). 
 
Table1: Patients characteristics. 
 All (n=22) Women (n=16) Men (n=6) 
Body composition    
Weight 71 ± 16 65 ± 10 86 ± 21* 
BMI (kg/m2) 30.7 ± 5 30 ± 5 32 ± 5 
Fat mass (%) 36 ± 7 37 ± 5 32 ± 8 
Free fat mass (kg) 45 ± 10 41 ± 5 58 ± 10* 
Trunk fat (%) 34 ± 6 38 ± 5 33 ± 8 
Waist circumference (cm) 100 ±13 97 ± 11 108 ± 16 
Risk factors, n (%)    
Obesity (%) 12 (55%) 8 (50%) 4 (67%) 
Former smoker (%) 3 (14%) 0 (0%) 3 (50%)* 
Hypertension (%) 20 (91%) 14 (88%) 6 (100%) 
Dyslipidemia (%) 15 (68%) 10 (63%) 5 (83%) 
Type 2 diabetes (%) 2 (9%) 1 (6%) 1 (17%) 
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Pre-diabetic (%) 8 (36%) 5 (31%) 3 (50%) 
AF (%) 11 (50%) 8 (50%) 3 (50%) 
AF (paroxysmal) (%) 4 (18%) 3 (19%) 1 (17%) 
COPD (%) 2 (9%) 0 (0%) 2 (33%)* 
Obstructive Sleep Apnea (%) 5 (23%) 2 (13%) 3 (50%) 
Clinical signs    
Resting HR (bpm) 73 ± 17 72 ± 16 74 ± 20 
SBP (mmHg) 135 ± 18 134 ± 18 138 ± 21 
DBP (mmHg) 70 ± 14 69 ± 16 72 ± 7 
BNP (pg/mL) 272 ± 180 273 ± 176 273 ± 206 
NYHA Functional Classification    
NYHA class I (%) 1 (5%) 0 (0%) 1 (17%) 
NYHA class II (%) 17 (77%) 12 (75%) 5 (83%) 
NYHA class III (%) 4 (18%) 4 (25%) 0 (0%) 
Medication     
ACE-i/ARB (%) 16 (73%) 11 (69%) 5 (83%) 
ß-Blockers (%) 18 (82%) 13 (81%) 5 (84%) 
Loop diuretics (%) 16 (73%) 10 (63%) 6 (100%) 
Statins (%) 14 (64%) 10 (63%) 4 (67%) 
Digoxin (%) 3 (14%) 3 (19%) 0 (0%) 
MRAs (%) 2 (9%) 1 (6%) 1 (17%) 
Cardiac Function    
LVEF (%) 59.4 ± 6.3 60 ± 6 57 ± 6 
E/e´  12.2 ± 3.1 12,9 ± 3.1 11 ± 2.6 
E/A 1.0 ± 0.5 1.02 ± 0.5 0,97 ± 0.5 
LVMI (gm/m2) 222 ± 96 193 ± 51 277 ± 138 
LAVI (mL/m2) 43 ± 12 44.1 ± 13 38.7 ± 7 
Physical fitness    
6MWT (m) 313 ± 91 312 ± 92 315 ± 95 
VO2 (ml/min/kg) 11.2 ± 2.3 11 ± 2.3 11.7 ± 2.4 
Quality of life Questioner     
MLHFQ total (points) 24 ± 24 29 ± 26 11 ± 10 
MLHFQ physical (points) 12 ±13 15 ± 14 4 ± 4 
MLHFQ emotional (points) 5 ± 7 6 ±7 3 ± 3 
BMI: Body mass index; AF: atrial fibrillation; COPD: chronic obstructive pulmonary disease; HR: 
heart rate; SPB: systolic blood pressure; DBP: diastolic blood pressure; BNP: brain natriuretic 
peptide; NYHA: New York Heart Association; ACEi/ARB: angiotensin-converting enzyme inhibitor 
and an angiotensin receptor blocker; MRAs: mineralocorticoid receptor antagonists; EF: ejection 
fraction; E/e´: ratio of early mitral transmitral flow velocity with early diastolic velocity of the mitral 
valve annulus; E/A: mitral ratio of peak early to late diastolic filling velocity; LVMI: left ventricle 
mass index; LAVI: left atrium volume index; 6MWT: six-minute walk distance test; VO2: relative 
oxygen uptake; MLHFQ: Minnesota Living With Heart Failure Questionnaire. Data are mean ± 
SD * p<0.05. 
 
Differences between self-reported and objective measures of PA 
The results of self-reported and objective measures of PA are described in 
Table 2. Accelerometer was used an average of 6.4±0.9 days, with a mean daily 
wear time of 790 minutes (13.2±1 hours/day). Compared to female, male wore 
the accelerometer during less time (741±86 vs 808±46 min/day, p=0.02). 
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Mean total activity volume from IPAQ was 152±183 MET/min/day, with older 
patients compared to younger, reporting lower activity volume (232±71 vs 72±114 
MET/min/day, respectively; p=0.03). From accelerometry, mean total activity 
volume was 550±239 CPM.  
Mean sedentary time was significantly lower in self-reported measurement 
(253±156 min.day-1) compared to accelerometry (392±104 min.day-1, p=0.001). 
No significant differences were found regarding to gender and age (p>0.05). 
Considering MVPA, self-reported daily time compared to accelerometer was 
higher (44±56 vs. 19.3±26 min/day, respectively; p<0.001). Applying the ≥10min-
bouts at MVPA criterion, the discrepancy between measurements was even 
higher (IPAQ= 44±56 min/day; Accelerometry= 1.1±2.4 min/day, p<0.001). From 
accelerometry data, it was possible to verify that only 5 patients accomplished 
with at least one bout of MVPA per week. Gender comparison showed that female 
compared to male, spent less time in 10 min-bouts of MVPA per day (0.2±0.8 vs 
3.4±7, respectively; p=0.01). Analysis by age showed that older patients spent 
significantly less time in MVPA (34 ± 31 vs 5±3, p=0.002) and did not perform 
10min-bouts of MVPA.  
Regarding to LPA, comparisons are not possible because it is measured 
only via accelerometry. Mean time in LPA was 379±128 min/day. Gender 
comparisons show that male compared to female spent less time in LPA 
(423±111 vs 260±91, respectively; p=0.005), while no significant difference was 
found comparing Youngers and elders (p>0.05). 
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Table 2: Descriptive PA levels from IPAQ and accelerometer variables.  
 All   
(n=22) 
Women        
(n=16) 
Men               
(n=6) 
≤76 y 
(n=11) 
>76 y 
(n=11) 
IPAQ-S Questionnaire      
IPAQ Total Activity (MET.min·d1) 152±183 149±204 159±123 232± 71 72±114* 
IPAQ Sitting (min·d–1) 253±156  226±141 323±184 280±138 224±173 
IPAQ MVPA (min·d–1) 44±56 43±62 46±35 66±64 21±34 
Accelerometer      
Total wear (min.d-1) 790±65 808±46 741±86* 803±60 775±68 
Total activity (counts.min-1) 550±239 574±214 489±313 641±271 459±170 
Sedentary time (min.d-1) 392±104 370±98 450±103 386 ± 123 396±85 
Light activity (min.d-1) 379±128 423±111 260±91* 383 ± 134 374±127 
MVPA (min.d-1) 19.3±26 15±21 31±37 34 ± 31 5±3* 
MVPA 10min-bouts (n) 0.07±0.14 0.02±0.07 0.1±0.2 0.13±0.18 0.00±0.00* 
MVPA 10min-bouts (min.d-1) 1.1±2.4 0.2±0.8 3.4±7* 2.2±3 0.00±0.00* 
Age group was divided by median. IPAQ: international physical activity questionnaire; MVPA: 
moderate to vigorous physical activity. Data are mean ± SD. *p<0.05.  
 
Correlation and agreement between self-reported and objective measures 
of PA  
To compare the validity and the accuracy of self-report and accelerometer-
derived PA were analysed: the standard error of the estimate (SEE), the validity 
correlation, the systematic error and the 95% limits of agreement (Table 3). 
Validation coefficients (correlation between self-report and accelerometer 
measured) were not significant in all PA levels, even after adjustments for gender 
and age. A significant mean difference (systematic error; p>0.05) between self-
reported and accelerometer-derived PA levels was detected in sedentary time 
and in 10-min-bouts-MVPA. By analysing the 95% limits of agreement, both PA 
levels presented a higher variation, ranging from -427.8 to 150 min/day for 
sedentary time, and from -65.2 to 150.5 min/day in 10-min-bouts-MVPA. The 
SEE was 96.7 min/day for sedentary time, 26.7 min/day for MVPA and 2.4 
min/day for 10-mim-bouts-MVPA (Table 3).  
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Table 3: Descriptive values for self-report physical activity levels. 
 Self-Reported 
(Mean ± SD) 
Mean Difference 
(95% LOA) 
r (p) SEE 
Sedentary time 253 ±156 -138.9 (-427.8; 150)* 0.368 (0.111) 96.7 
MVPA 44 ± 56 24.4 (-88.9; 137.8) 0.261 (0.266) 26.7 
MVPA 10-min-bouts 44 ± 56 42.6 (-65.2; 150.5)* 0.236 (0.317) 2.4 
Mean Difference= self-reported - objective measured parameter (expressed in min/day); LOA = 
limits of agreement (mean difference ±1.96 SD); r = Pearson correlations between self-reported 
and measured parameters (validation coefficient); SEE = standard error of the estimate 
expressed in min.d-1; *p<0.05 for comparison between self-reported and measured parameters. 
 
Separate Bland-Altman plots were build-up for sedentary time, total MVPA 
and 10min-bouts-MVPA (Figure 1). Both MVPA plots show a linear tendency, 
which is not acceptable for the agreement between the two methods. Analysis of 
10min-bouts of MVPA revealed that at higher levels of PA, the difference between 
self-reported data and accelerometers data becomes greater. In these cases, the 
self-reported levels were greater than what was observed by the tri-axial 
accelerometer. 
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Figure 1: Bland-Altman plot of the mean bias and 95% limits of agreement for time spent 
in (A) sedentary time, (B) MVPA and (C) 10-min-bouts-MVPA. Black line indicates mean 
difference (systematic error); red lines indicate the 95% limits of agreement (mean ± 1,96 
SD). SD: standard deviation. MVPA: moderate-to-vigorous physical activity. 
 
Associations between objective measures of PA with prognostic indicators 
The association between objective measures of PA and prognostic 
indicators is showed in Table 4).  Total activity (CPM) was significant associated 
with VO2 (r=0.498, p=0.04). Furthermore, MVPA was positively correlated with 
VO2 (r=0.512; p=0.02) and 6MWT (r=0.652; p=0.008), and inversely correlated 
with QoL (r=-0.490; p=0.04). In addition, 10min-bouts of MVPA was positively 
correlated with VO2 (r=0.559; p=0.04) and inversely correlated with QoL (r=-
0.465; p=0.03). No significant correlations were found between sedentary time or 
LPA with any prognostic indicators. 
 
Table 4. Partial correlations between accelerometer measured sedentary time 
MVPA, MVPA 10min-bouts and prognosis values. 
 VO2 6MWT QoL BNP E/e´ 
Total activity (CPM) 0.509* 0.271 -0.371 -0.097 -0.068 
Sedentary time -0.323 -0.012 -0.128 -0.025 0.203 
Light activity 0.367 0.225 -0.211 0.318 0.183 
MVPA 0.512* 0.652* -0.490 -0.068 -0.133 
MVPA 10min-bouts 0.459* 0.427 -0.559* 0.022 -0.016 
CPM: counts per minute; MVPA: moderate to vigorous physical activity; VO2: oxygen uptake; 
6MWT: six-minute walk distance test; QoL: quality of life; BNP: brain natriuretic peptide; E/e´: 
ratio of early mitral transmitral flow velocity with early diastolic velocity of the mitral valve annulus. 
* p<0.05.  
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DISCUSSION 
The main findings of this study suggest that: i) in comparison to 
accelerometer, self-reported PA from IPAQ-SF underestimates sedentary time 
and overestimates time spent in MVPA in HFpEF patients, ii) HFpEF patients 
spent only a minority of their daily activity in MVPA, and iii) only MVPA measured 
from accelerometer was correlated with functional capacity and QoL. 
Despite the evidence showing that questionnaires are valid and reliable in 
measuring PA, their correlation with objective measures (e.g. accelerometers) is 
far from satisfactory (Koolhaas et al., 2018; Lee et al., 2011; Prince et al., 2008; 
Skender et al., 2016), which limits PA-based decisions. In agreement with these 
observations, our data highlights for the first time the disparity of PA 
measurements obtained with IPAQ-SF in comparison to accelerometer-derived 
data in HFpEF patients, with the former overestimating MVPA and 
underestimating sedentary/sitting time. We also verified the absence of 
agreement between self-reported and accelerometer-derived sedentary time and 
MVPA. This means that measuring PA levels in the same person with these 
instruments leads to important variations in magnitude and concordance of the 
measured outcome.  
According to self-reported PA, 59% of our patients would meet the 
international recommendations for MPVA (>150 min/week of MVPA). However, 
when we confronted with accelerometer-assessed data, this percentage dropped 
to 27% (without the 10min bout criteria) but decreased to zero when the 10min-
bouts criteria was considered. A similar finding was found in the Women’s Health 
Study, where 67% of women meet PA recommendations when considering 
results from self-reported methods, but when considering accelerometry (using 
10min-bouts criteria), this percentage was 19% (Shiroma et al., 2015). The lack 
of correlation and agreement between methods may be related with different 
constructs measured by the two instruments. While the accelerometer measures 
the motion through acceleration of body mass, the IPAQ-SF questionnaire 
measures the time spent in specific behaviours (Troiano et al., 2014). Therefore, 
the use of objective measures of PA seems to have a particular importance to 
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avoid bias in populations with limited physical function and limited past 
knowledge and experience on regular PA (Prince et al., 2008). 
Given the growing recognition of the impact of PA levels in the prognosis of 
HFpEF patients, a rigorous characterization of their patterns is crucial for 
prescribing tailored life-style changes. In our study, descriptive accelerometer 
data shows that HFpEF patients spent 50% of recorded time in sedentary 
behaviours, 47.5% at LPA and only 2.5% at MVPA (0.1% with 10min-bout 
criteria). Similar patterns were recently observed by Yavari and colleagues, 
where HFpEF patients reported to spent most of their waking time in sedentary 
behaviours while their daily activity was mainly comprised of LPA, and just a few 
minutes in MVPA (Yavari et al., 2017). Overall, these patterns of PA are similar 
to those described for adults older than 60 years, where sedentary time 
accounted for approximately for 60% of their waking time, LPA for 40% and 4% 
for MVPA (Spittaels et al., 2012). Although the patterns of time spent in each 
category are similar, our results show that the proportion of time spent in LPA 
was almost 10% higher, while sedentary time was 10% lower. While the fact that 
our patients were in optimal medical control may have accounted for that, 
differences in the type of accelerometers and cut-points also may have influenced 
the results. In fact, we used the GT3X triaxial accelerometer with the low 
frequency extension filter, which was shown to be more sensitive to capture 
slower movements, translating into decreased sedentary time and increase time 
in all PA intensities (Migueles et al., 2017). In addition, although specific cut-
points for GT3X triaxial accelerometer have not been validated in HFpEF 
patients, we used cut-points for older adults validated with the GT3X, which we 
believe are more representative for our population.    
With respect to prognosis, it was recently shown in the NEAT-HFpEF trial 
that accelerometer-derived total daily PA in HFpEF patients was associated with 
better 6MWT, NYHA functional class, QoL, and NT-proBNP levels (Snipelisky et 
al., 2017). Our study adds the novelty that only time spent in MVPA was 
significantly associated with important clinical outcomes as VO2, 6MWT and QoL, 
but not with E/e´ or BNP levels. Thus, it seems that intensity is a requirement for 
significantly impacting the patient’s prognosis. Corroborating this hypothesis, it 
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was recently shown a dose-response relationship between MVPA and risk of 
hospitalization or mortality in HFpEF patients (Hegde et al., 2017). In addition, it 
should be noted that only a minority of patients achieved the weekly 
recommendations of MVPA (without the 10min-bouts criteria). While any increase 
in the amount of PA may translate into some health benefits (Physical Activity 
Guidelines Advisory Committee Scientific Report, 2018), our data suggests that 
patients should be educated about the importance of reducing their sedentary 
time and engage in more MVPA for greater benefits. 
 
  
  
CRISTINE SCHMIDT | HEART FAILURE WITH PRESERVED EJECTION FRACTION: FROM PROGNOSIS TO CARDIAC FUNTION | 
 
90 
STUDY LIMITATIONS 
Some limitations should be acknowledged. The small sample size limits 
inferences regarding the agreement between PA measurements from IPAQ-SF 
questionnaire and PA measures derived from triaxial accelerometer. This report 
has a cross-sectional design, which limits the establishment of causal inferences 
regarding PA and its influence on prognostic indicators, and the sample size 
preclude the determination of predictive models. Moreover, the sample in this 
study does not reflect all stages of the disease course. 
 
CONCLUSION 
Our results suggest that IPAQ-SF, compared to objectively measured PA, 
underestimates sedentary time and over-estimates time spent in MVPA in 
patients with HFpEF, limiting its use to support accurate recommendations. 
Accelerometer-derived data shows that HFpEF patients spent only a minority of 
their time involved in MVPA, which was the only PA pattern positively associated 
with prognostic indicators, highlighting the importance of reducing sedentary time 
and performing MVPA throughout the day. 
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STUDY III 
 
CHRONIC EXERCISE TRAINING REDUCES LEFT VENTRICLE STIFFNESS 
IN AN ANIMAL MODEL OF HEART FAILURE WITH PRESERVED EJECTION 
FRACTION 
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ABSTRACT  
 
Rational: In heart failure with preserved ejection fraction (HFpEF), microvascular 
endothelial inflammation is responsible for cardiomyocyte stiffness and interstitial 
fibrosis which leads to diastolic left ventricle (LV) dysfunction. Nonetheless, 
HFpEF optimal treatment remains widely undefined. 
Purpose: To assess the impact of exercise training at the level of cardiac function 
and characterize underlying cellular and molecular changes. 
Methods: Nine-week old ZSF1 obese rats (Ob n=20) were divided into two 
groups: sedentary (ObSED, n=10) and exercised (ObEX, n=10). At the 16th week 
of life, the ObEX group was submitted to treadmill exercise training for 4 weeks, 
5 days per week, 60 min per day, at a speed of 20m/min. At the end of the protocol 
(20th week), all animals performed a maximal oxygen consumption (VO2max) 
test, hemodynamic evaluation, and samples were collected for analysis. Plasma 
proteins were analysed by ELISA. Samples from LV were collated for: i) 
histological analysis (cross-sectional area (CSA), collagen content) and ii) 
passive tension analysis in skinned cardiomyocytes.  
Results: Exercise training improved VO2max (21±2.5 vs 17±1.8 mL.Kg-1.min-1, 
p=0.005). The end-diastolic pressure volume relationship had a trend to decrease 
in ObEX that, together with the decreased passive tension presented in skinned 
cardiomyocytes (p<0.05) and reduced collagen/muscle ratio (p<0.05), suggests 
a reduction in myocardial stiffness. No significant differences were observed 
between the groups in CSA. In addition, exercised animals showed reduced 
levels of several circulating biomarkers, such as markers of inflammation, 
endothelial dysfunction, oxidative stress, neurohumoral activation and 
extracellular matrix remodelling (p<0.05).  
Conclusion: Chronic exercise training improved exercise capacity and 
attenuated LV diastolic function and in rats with HFpEF. These improvements 
were associated with decreased cardiomyocyte passive tension and extracellular 
matrix fibroses. Moreover, exercise training reduced circulating levels of 
inflammatory cytokines and markers of endothelial dysfunction, oxidative stress, 
neurohumoral activation and extracellular matrix remodelling. 
 
Key-words: exercise training, LV stiffness, HFpEF, circulating biomarkers.  
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INTRODUCTION 
Heart Failure (HF) with preserved ejection fraction (HFpEF) is a global 
clinical problem, accounting for more than 50% of all HF cases (Dunlay et al., 
2017). Its prevalence has strikingly grown due to increasing prevalence of risk 
factors such as obesity, hypertension and diabetes in an ageing population 
(Dunlay et al., 2017). Heart Failure with preserved ejection fraction is responsible 
for frequent hospitalizations, high consumption of resources and poor prognosis, 
and no treatment has yet been shown to reduce morbidity or mortality (Owan et 
al., 2006; Ponikowski et al., 2016). Ventricular diastolic dysfunction is a central 
feature of HFpEF, caused by impaired relaxation and increased diastolic stiffness 
(Redfield, 2016).  This is mediated, at least in part, by extracellular matrix 
remodeling (van Heerebeek et al., 2012) and changes in the expression and 
phosphorylation of cytoskeletal proteins (Hamdani et al., 2013). 
Exercise training is emerging as an important ally for the clinical 
management of health-related outcomes in HFpEF patients. Different meta-
analysis of randomized clinical trials shows that exercise training, in comparison 
to usual care, improves functional capacity, cardiorespiratory fitness and quality 
of life (Fukuta et al., 2016; Pandey et al., 2015). It has been proposed that non-
cardiac peripheral adaptations are the major contributors (Haykowsky & Kitzman, 
2014). However, some clinical (Dieberg et al., 2015; Pearson et al., 2017) and 
pre-clinical studies (Hidalgo et al., 2014; Marshall et al., 2013) support the 
hypothesis that exercise training may also improve diastolic function. Whether 
this will translate into a greater peak cardiac output remains unknown. 
Understanding the pathways that mediate these cardiac benefits could yield 
novel therapeutic approaches based on agents that mimic or potentiate the 
physiological benefits of exercise. In this sense, it was already shown that chronic 
free-wheel running improved cardiac stiffness in a genetic mouse model of 
HFpEF, an effect that was mediated by the reduction on titin-based passive 
stiffness in a phosphorylation-dependent manner (Hidalgo et al., 2014; Slater et 
al., 2017). Using the Yucatan miniature swine model of HFpEF, Marshal and 
collaborators also showed that treadmill exercise training attenuated diastolic 
impairment by reducing extracellular matrix (ECM) fibrosis (Marshall et al., 2013).  
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Despite these molecular insights, it is important to highlight that none of 
these animal models fully mimic the spectrum of changes found in humans with 
HFpEF (Ponikowski et al., 2016). Recently, our group contributed to surpass 
these limitations by validating the ZSF1 obese animal model for HFpEF (Hamdani 
et al., 2013). The ZSF1 obese animals exhibit several features of human HFpEF 
such as the presence of comorbidities, exercise intolerance, and diastolic 
dysfunction with preserved systolic function (Hamdani et al., 2013, Leite et al., 
2015), placing this model one step ahead towards clinical translation (Lourenco 
et al., 2018). Therefore, by using this animal model of HFpEF, we aimed to 
assess the impact of exercise training at the level of cardiac function and 
characterize underlying cellular and molecular changes. 
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METHODS  
 
Animal model 
The animal protocol was approved by the ethics committee of Faculty of 
Medicine of Porto and was conducted in accordance with the Guide for the Care 
and Use of Laboratory Animals published by the National Institutes of Health (NIH 
publication no. 85-23, revised 1996). 
Nine-week-old rats ZSF1 obese (Zucker diabetic fatty/Spontaneously 
hypertensive heart failure F1 hybrid rats) (ZSF1 Ob, n=17) were obtained from 
Charles River (Barcelona, Spain). Animals were housed in groups of 2 animals 
per cage, maintained on a 12-hour light-dark cycle, at a room temperature of 
22°C, fed with Purina Diet (#5008) and water ad libitum. Rats were allowed 1 
week of adaptation to laboratory conditions before experiments. At 16th week of 
life, the ZSF1 Ob rats were randomly divided into two groups, obese sedentary 
(ObSED, n=7; normal activity at the cage) and obese exercised (ObEx, n=10; 
aerobic exercise training). Exercise training protocol consisted of running on the 
treadmill (76-0896, PanLab Harvard Apparatus) 5 days per week, 1 hour per day, 
at a speed of 20m/min, for 4 weeks. The sedentary group was submitted to a 
stationary treadmill in order to minimize environmental confounders among the 
animals not subjected to the exercise protocol. The protocol was interrupted 48 
hours before terminal evaluation and sample collection to avoid confounding with 
acute effects of the last training session.  
  
Peak effort testing with oxygen consumption determination 
At 20th week, animals underwent an exercise tolerance test with oxygen 
consumption (VO2) measurement (LE8700C, OxyletPro System, PanLab 
Harvard Apparatus). Initially, animals were adapted to treadmill at 9m/min for 3 
minutes, followed by a rapid effort escalation to assess peak oxygen consumption 
(VO2peak). Velocity was changed to 18m/min and then stepped up 3m/min at 
1min intervals. Treadmill was stopped whenever animals were unable/unwilling 
to maintain pace, as defined by incapability to come off the back of the treadmill 
lane for >3 seconds. Gas concentrations (O2 and CO2), speed and covered 
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distance were continuously recorded. Data analysis was performed with the aid 
of software (Metabolism V2.2.01, Panlab Harvard Apparatus®). 
 
Hemodynamic evaluation  
Forty-eight hours after exercise testing, we performed terminal 
hemodynamic evaluation. After sedation (100 μg.kg-1 and 5 mg.kg-1 
intraperitoneal fentanyl and midazolam, respectively), animals were anesthetized 
by inhalation of a mixture of sevoflurane (2.5–3% sevoflurane; Penlon Sigma 
Delta) and oxygen, intubated for mechanical ventilation (TOPO, Kent Scientific) 
and placed over a heating pad (body temperature was maintained at 38°C). A 
peripheral venous catheter was introduced in the right femoral vein for 
intravenous warm Ringer’s solution infusion (8 mL.kg-1.h-1; NE-1000, New Era 
Pump Systems). A left thoracotomy allowed assessing the heart for insertion of 
a pressure-volume catheter in the LV through the apex (SPR-838 Millar 
Instruments, respectively). A probe (Transonics) was placed around the 
ascending aorta that allowed CO measurement (Active Redirection Transit Time 
Flowmeter, Triton Technology). Signals were continuously acquired (MPVS 300, 
Millar Instruments), recorded at 1000 Hz (ML880 PowerLab 16/30, 
ADinstruments), and analysed (PVAN 3.5, Millar Instruments). Recordings were 
obtained at suspended end-expiration. The LV catheter was advanced to record 
systemic arterial pressure. Parallel conductance was assessed with hypertonic 
saline. After euthanasia (100 mg.kg-1 intravenous pentobarbital), blood (4mL) 
was collected for storage (-80ºC) and for volume calibration (910–1048, Millar 
instruments). LV volumes were varied using transient inferior vena cava 
constrictions by adjusting a sling around the inferior vena cava. Blood was used 
for volume calibration in standard wells. Heart, LV+septum, lung, skeletal muscle 
(gastrocnemius, soleus and tibialis anterior) were collected, weighed and 
immediately snap frozen on liquid nitrogen, and stored at 80oC. Tibia length was 
measured and then used to normalizations. Body surface area was defined as 
9.1*(weight)2/3 (Hamdani et al., 2013).   
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Biomarkers quantification  
Blood samples were obtained through RV cannulation, were collected in 
EDTA tubes after hemodynamic evaluation. Samples were centrifuged at 5000 
rpm for 15 minutes at 4°C. Serum was subsequently separated and frozen. 
Before the quantification, serum was centrifuged at 20 000 rpm for 15 minutes at 
4°C for lipid separation. Quantitative enzyme immunoassays (ELISA) of 
interleukin- 6 (IL-6), IL-10, intercellular adhesion molecule-1 (ICAM-1)/CD54, 
metalloproteinase (MMP)-2, MMP-9, tissue inhibitor of metalloproteinase-1 
(TIMP-1) (R&D Systems, #R6000B, #R1000, #RIC100, #MMP200, #RMP900, 
#RTM100, respectively), NT-pro-BNP, malondialdehyde (MDA), high sensitivity 
C-Reactive Protein (hs-CRP), TNF-alpha, vascular adhesion molecule-1 (VCAM-
1)  (MyBioSource, #MBS704791, #MBS727531, #MBS281245, #MBS824520, 
#MBS2502676 respectively) and protein carbonyl content (Abcam, #ab126287) 
were measured according to the manufacturer’s instructions. Results were 
analysed using an ELISA plate reader (UVM-340, ASYS Hitech GmbH). A 
calibration curve was constructed by plotting the absorbance values at 450nm 
(with specific correction, according to manufacturer’s protocol) and 
concentrations of unknown samples were determined.  
 
Histological studies  
Slices of LV tissue were submersed in a fixative solution of 4% 
paraformaldehyde by diffusion for 24 hours and subsequently dehydrated with 
graded ethanol and included in paraffin blocks. Xilene was used in the transition 
between dehydration and impregnation. LV blocks were embedded in the upright 
position in order to distinguish the endocardium, midwall, and the epicardium of 
the LV free wall in cross sections. Serial sections (5 μm of thickness) of paraffin 
blocks were cut by a microtome (Minot type microtome (RM2125RTS, Leica, 
Nussloch, Germany) and mounted on silane-coated slides. The slides were 
dewaxed in xylene and hydrated through graded alcohols finishing in phosphate 
buffered saline solution prepared by dissolving Na2HPO4 (1.44 g), KH2PO4 
(0.24 g), NaCl (8 g), KCl (0.2 g) and adjusting pH to 7.2. Deparaffinized sections 
from LV were stained for haematoxylin-eosin, performed by immersing slides in 
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Mayer’s haematoxylin solution for 3–4 min followed by immersion in 1% eosin 
solution for 7 min, dehydration with graded alcohols through xylene, and mounted 
with DPX. Stained sections of slides were digitally photographed (Olympus XC30 
Digital colour Camera). Cardiomyocytes surface area (CSA) was measured using 
imaging software (cell^B, Olympus). We analysed 5 random animals per group, 
10 photos per animal (magnification of X400) and only nuclei-centred 
cardiomyocytes were considered for analysis. In order to determine the amount 
of cardiac fibrosis, slides were immersed in picrosirius red for 2h, washed with 
acid water (0.05% acetic acid) and mounted after de-hydration as described 
before (Falcao-Pires et al., 2011b). Digital images (magnification of X400) were 
analysed, using image analysis software (Image-Pro Plus version 6.0, Media 
Cybernetics Inc.), from 5 random animals per group, 10 photos per animal. 
 
Isolated cardiomyocyte 
Force measurements were performed in single and mechanically isolated 
cardiomyocytes as previously described (Borbely et al., 2005; Falcao-Pires et al., 
2011a). Myocardial samples (10-15 mg wet weight) from rat hearts subjected to 
the exercise protocol described above were defrosted in cold relaxing solution, 
mechanically disrupted, and incubated for 5 minutes in relaxing solution 
supplemented with 0.2% Triton X-100, in order to remove membrane’s structures. 
Afterwards, single cardiomyocytes were attached between the force transducer 
and the piezoelectric motor with glue. Passive tension was measured at 
sarcomere lengths ranging between 1.8 µm to 2.3µm (0.1 µm step increases) at 
15°C.  Force values were normalized for myocyte cross-sectional area.  
 
Statistical Analysis 
The Shapiro-Wilk or Kolmogorov–Smirnov test was performed to check 
normality of the data. Between-group comparisons of normal data were 
performed with independent sample t-test. Non-normal data were analysed with 
nonparametric tests, namely the Mann-Whitney U Test. Data are expressed as 
means ± SD. Statistical analysis was performed using the GrapPad Prism 8 and 
the statistical significance was set at p <0.05. 
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RESULTS 
 
General morphometric features  
Absolute and normalized (to tibia length) morphometric parameters are 
presented in Table 1. In comparison to ObSED group, ObEX group presented a 
significant increase on gastrocnemius (1.8 vs. 2.0 mg, p<0.001) and tibialis 
anterior muscle weight (0.62 vs. 0.69 mg, p<0.001), even when adjusted for tibia 
length (43.7 vs. 52.6 mg/mm, p˂0.001 and 16.2 vs. 18.1 mg/mm, p=0.02, 
respectively).  
 
Table 1. General morphometric characterization. 
 ObSED ObEX 
BW (g) 604 ± 49 624 ± 36 
TL (mm) 38.5 ± 1.1 38.5 ± 0.8 
Heart (g) 1.7 ± 0.17 1.8 ± 0.11 
Heart W/TL (g.mm-1) 438 ± 42 454 ± 31 
LV+IVS (g) 1.5 ± 0.18 1.6 ± 0.11 
LV+IVS/TL (mg.mm-1) 40.5 ± 4.6 41.6 ± 3.2 
Lung (g) 2.6 ± 0.3 2.8 ± 0.6 
Lung/T (mg.mm-1) 66.7 ± 8.2 71.7 ± 16.6 
Gastrocnemius (g) 1.8 ± 0.08 2.0 ± 0.10* 
G/TL (mg.mm-1) 47.3 ± 1.4 52.6 ± 2.4* 
Soleus (g) 0.17 ± 0.02 0.18 ± 0.02 
S/TL (mg.mm-1) 4.4 ± 0.5 4.7 ± 0.7 
Tibialis anterior (g) 0.62 ± 0.05 0.69 ± 0.03* 
TA/TL (mg.mm-1) 16.2 ± 1.5 18.1 ± 1.1* 
BW: body weight; TL: tibia length; LV+IVS: left ventricle+interventricular septum; G: 
gastrocnemius; S: soleus; TA: tibialis anterior. Data are mean ± SD. *p<0.05 vs ObSED. 
 
Effects of exercise training on exercise tolerance  
According to respiratory quotient, none of the groups reached the criteria 
for maximum VO2. The ObEX group showed increased exercise capacity 
compared with ObSED group (Figure 1), as shown by their greater VO2peak 
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(21.1±2.5 vs. 17.2±1.8 mL.Kg-1.min-1, p=0.005), total running time (7.51 vs 9.22 
minutes, p=0.005), and maximum running speed (30 vs 26 m/min, p=0.02). 
 
 
Figure 1: Exercise tolerance test data. Exercise training increased VO2 peak, total 
running time and maximum running speed. VO2 peak: peak oxygen consumption. Data 
are mean ± SD.*p<0.05 vs ObSED.  
 
Effects of exercise training on cardiac function  
Hemodynamic evaluation did not show significant differences between both 
groups (Table 2). However, exercise training was capable to induce a decrease 
in the end-diastolic pressure-volume relationship that was almost significant 
(0.036 vs. 0.029 µL.cm-2, p=0.07). When compared with a reference control group, 
previously published by us (Hamdani et al., 2013), we found that βEDPVRi was 
significantly greater in the ObSED group (p<0.05 vs. Wistar-Kyoto), but not in 
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ObEX group (p>0.05 vs. Wistar-Kyoto), further suggesting that the exercise 
training protocol improved diastolic stiffness. 
 
Table 2. Invasive hemodynamic evaluation parameters. 
 ObSED ObEX 
BSA (cm2) 652 ± 6 660 ± 8 
HR (min-1) 362 ± 9 337 ± 8 
Pressure   
MAP (mmHg) 143 ± 4 132 ± 4 
LVSP (mmHg) 175 ± 4 168 ± 4 
LVEDP (mmHg) 11 ± 1 11 ± 1 
dP/dtmin (mmHg.s-1) -10662 ± 1939 -11915 ± 1926 
dP/dtmax (mmHg.s-1) 10631 ± 2077 9789 ± 1063 
t (ms) 10.2 ± 0.5 10.3 ± 0.5 
Volume   
CI (µL.min-1.cm-2) 124 ± 7 133 ± 4 
EF (%) 58 ± 3 54 ± 1 
LVEDVi (µL.cm-2) 7.0 ± 0.7 7.6 ± 0.2 
Eai (mmHg. µL-1.cm-2) 392 ± 122 342 ± 30 
ESPVRi (mmHg. µL-1.cm-2) 2.1 ± 0.3 2.2 ± 0.3 
EDPVR b i (µL.cm-2) 0.036 ± 0.009 0.029 ± 0.003 
BSA: body surface area; HR: heart rate; MAP: mean arterial pressure; LVSP: left ventricular 
systolic pressure; LVEDP: left ventricular end diastolic pressure; dP/dtmin: maximum rate of 
pressure fall; dP/dtmax: maximum rate of left ventricular pressure rise; t: time constant of 
isovolumetric relaxation; CI: cardiac index; EF: ejection fraction; LVEDVi: left ventricular end 
diastolic volume indexed for BSA; Eai: arterial elastance indexed for BSA; ESPVRi: slope of the 
linear end systolic pressure volume relationship with volumes indexed for BSA; EDPVRi: end 
diastole pressure volume relationship; βi: chamber stiffness constant for indexed volumes, 
derived from exponential EDPVR. Data are mean ± SD.*p<0.05 vs ObSED. 
 
Effects of exercise training on cardiomyocyte stiffness  
To evaluate whether exercise training was capable to modulate passive 
tension at myofilamental level, we stretched isolated skinned cardiomyocytes at 
sarcomere lengths ranging from 1.8µm to 2.3µm (0.1 µm step increases), in order 
to obtain passive tension-sarcomere length relationships. Cardiomyocytes 
harvested from the LV free wall of ObEX presented marked downward-shifts in 
passive tension at sarcomere lengths relationships compared to ObSED at 
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myofilamental level from 2.1µm onward (p<0.05) (Figure 2). The passive tension 
for the same sarcomere lengths relationships was steeper in the ObSED group, 
suggesting intrinsic changes at the myofillamental level. No significant 
differences of active tension were observed between groups (P>0.05 vs. 
ObSED). 
 
 
Figure 2: Effect of exercise training on passive tension in LV skinned 
cardiomyocytes. Exercise training result in downward-shifts in passive tension at 
sarcomere lengths relationships compared to ObSED at myofilamental level from 2.1µm 
onward. Data are mean ± SD. *p<0.05 vs ObSED. 
 
Effects of exercise training on histological parameters 
When analysing the cross-sectional area of LV (Figure 3A, C), no 
differences were detected between groups. However, the ratio collagen/muscle 
was significantly reduced in ObEX when compared to ObSED group (0.08 vs. 
0.12 p<0.001) (Figure 3D).  
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Figure 3: Effects of exercise training on histological parameters. No differences 
were detected in cross-section area (A-C) while exercise training reduced 
collagen/muscle ratio (D) in ObEX. Data are mean ± SD. *p<0.05 vs ObSED. 
 
Effects of exercise training on plasma levels of biomarkers 
Results from plasma levels of biomarkers are presented in table 3 and 
revealed that the expression of pro-inflammatory cytokines IL-6 (p=0.04), CRP 
(p=0.004) and TNF-α (p=0.01) were decreased in ObEX group when compared 
to ObSED. Similar findings were observed regarding circulating markers of 
oxidative stress (evaluated by PCC; p= 0.02), endothelial activation (ICAM-1; 
p=0.03) and cardiac overload (NT-proBNP, p=0.001) in ObEX group. Finally, 
ECM remodeling markers, such as MMP-9 (p<0.001) and MMP-9/TIMP-1 
(p=0.03), were also reduced in ObEX group compared with ObSED.  
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Table 3: Plasma levels of circulating biomarkers.  
Biomarkers ObSED (n=7) ObEX(n=8) 
IL-6 (pg/mL)  2983 ± 2084 912.4 ± 1274* 
CRP (ng/mL)  7.2 ± 3.8 1.842 ± 0.8* 
TNF-α (pg/mL) 509 ± 301 177±105* 
ICAM-1 (pg/mL)  47492 ± 22889 28403 ± 7142* 
VCAM-1 (pg/mL) 44.4 ± 51 57 ± 34 
PCC (nmol/mg)  292 ± 203 151 ± 86* 
MDA 19.31 ± 5 20.48 ± 8 
NT-proBNP (pg/mL)  1403 ± 491.5 581.4 ± 189* 
MMP-2 19728 ± 7760 19785 ± 7862 
MMP-9 103 ± 29 33 ± 23* 
TIMP-1 17623 ± 8778 10651 ± 4187 
MMP-9/TIMP-1  0.008 ± 0.005*† 0.003 ± 0,001* 
IL-6: interleukin-6; CRP: C-reactive protein; TNF-α: tumor necrosis factor alpha; ICAM: 
intercellular adhesion molecule; VCAM: vascular adhesion molecule; PCC: protein carbonyl 
content; MDA: malondialdehyde; NT-proBNP: N-terminal pro-brain natriuretic peptide; MMP-2: 
matrix metalloproteinase-2; MMP-9: matrix metalloproteinase-9; tissue inhibitor of 
metalloproteinase-1; MMP-9/TIMP-1: matrix metalloproteinase-9/tissue inhibitor of 
metalloproteinase-1 ratio.  Data are mean ± SD.*p<0.05 vs ObSED.  
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DISCUSSION  
The present study demonstrates beneficial effects of moderate exercise 
training in the ZSF1 rat model of HFpEF. We showed that exercise training: i) 
improved exercise capacity, ii) attenuated LV stiffness, and iii) reduced circulating 
biomarkers of inflammation, endothelial activation, oxidative stress, 
neurohumoral activation and ECM remodeling. 
Exercise intolerance is a primary symptom in patients with HFpEF, 
manifested by early fatigue and dyspnea, which is a strong determinant of 
prognosis and reduced quality of life (Upadhya et al., 2015). While drugs 
interventions have failed to improve exercise capacity and quality of life in HFpEF 
patients, exercise training has been shown to improve both outcomes (Fukuta et 
al., 2016). Using a previously validated animal model of HFpEF (Hamdani et al., 
2013), the present study corroborates that exercise training improves exercise 
capacity in HFpEF. Although the improvement on exercise capacity by exercise 
training is well recognized, the physiological mechanisms underlying these 
changes in HFpEF are poorly understood. Current published data suggests that 
the greater VO2peak found in HFpEF patients after a training program is mainly 
because of non-cardiac peripheral adaptations, as no study has yet shown to 
improve cardiac output (Fu et al., 2016; Haykowsky et al., 2012). However, both 
clinical (Dieberg et al., 2015; Pearson et al., 2017) and pre-clinical studies 
(Hidalgo et al., 2014; Marshall et al., 2013) support the hypothesis that exercise 
training improves diastolic function in HFpEF setting, which may also account for 
a greater exercise response. Consistently, our data showed that exercise training 
modulates LV compliance and distensibility in HFpEF animals. We found a 
borderline-significant decrease in end-diastolic pressure-volume relationship, 
which was accompanied by reduced cardiomyocyte stiffness. In addition, 
exercised animals showed lower circulating levels of NT-proBNP, suggesting 
reduced wall stress, possibly due to a less stiffer heart (Bordbar et al., 2012). 
Whether exercise training can modulate LV compliance and distensibility in 
HFpEF remains to be explored, but these diastolic variables were shown to be 
modulated by exercise training in healthy middle age individuals (Howden et al., 
2018) and in healthy seniors (Bhella et al., 2014).  
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So far, the literature does not elucidate how exercise training could improve 
diastolic function in HFpEF patients. Edelmann and colleagues demonstrated 
that exercise training improved LV diastolic function and promoted atrial reverse 
remodelling without change in LV mass, suggesting a switch from pathologic to 
physiologic hypertrophy (Edelmann et al., 2011). In addition, exercise training 
was associated with a significant reduction in procollagen type I plasma levels, 
suggesting that improvement in diastolic function may be associated with 
reduced collagen turnover (Edelmann et al., 2011). Our data strengthens the 
hypothesis that exercise training enhances cardiac function by decreasing 
cardiomyocyte passive tension and LV fibrosis. We observed a downward-shift 
in passive tension at sarcomere lengths relationships from LV cardiomyocytes of 
ObEX rats comparing to those extracted from ObSED. These findings confirm an 
increase in LV compliance promoted, at least in part, by intrinsic cardiomyocyte 
changes. This is supported by previous data showing that chronic voluntary 
running decreases titin-based passive stiffness in a phosphorylation-dependent 
manner in mice with diastolic dysfunction (Slater et al., 2017) (Kotter et al., 2013). 
In addition, it is also possible that the improved LV compliance could be due to 
adaptations at the ECM level, as we found that exercise training attenuated LV 
collagen formation and reduced systemic levels of MMP9 and MM9/TIMP1 ratio. 
Similarly, treadmill exercise training was shown to attenuate diastolic impairment 
by reducing fibrosis in the Yucatan miniature swine model of HFpEF (aortic-
banded to produce concentric LV hypertrophy) (Marshall et al., 2013). Our data 
suggests that the overall beneficial effect of exercise on cardiac function might 
be due to both cardiomyocyte’s intrinsic and extrinsic mechanisms.  
It has been proposed that myocardial remodelling and dysfunction in HFpEF 
is triggered by low-grade chronic systemic inflammation induced by comorbidities 
(Paulus & Tschope, 2013). This persistent inflammatory state causes coronary 
microvascular endothelial inflammation and oxidative damage, leading to lower 
nitric oxide bioavailability and PKG activity, thus contributing to LV stiffness by 
inducing hypertrophy and hypophosphorylation of titin (Franssen et al., 2016; 
Paulus & Tschope, 2013). In addition, endothelial activation of cell adhesion 
molecules by inflammation would favours the migration of monocytes into the 
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subendothelium and stimulates the conversion of fibroblasts to myofibroblasts by 
release transforming growth factor β (TGF-β). This would also contribute to 
cardiac stiffness, as myofibroblasts are responsible for depositing collagen in the 
interstitial space.  The majority of these features have also been shown to be 
present in the ZSF1 obese animal model (Hamdani et al., 2013; Leite-Moreira et 
al., 2018). In the current work, we found that ObEX animals had reduced levels 
of circulating inflammatory cytokines (CRP, IL-6 and TNF-α), oxidative stress 
(PCC), and endothelial activation (ICAM-1). Thus, we hypothesized that these 
systemic effects promoted by exercise training were capable to interfere with the 
cascade of events leading to increased diastolic left ventricular stiffness and heart 
failure development. 
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CONCLUSION 
 Our findings suggest that moderate exercise training improves exercise 
capacity and attenuates LV diastolic stiffness in the ZSF1 obese rat model of 
HFpEF. This was paralleled by reduced circulating levels of inflammatory 
cytokines and markers of endothelial dysfunction and oxidative stress. These 
results provide novel mechanistic insight into the benefits of training in a clinically 
meaningful translational animal model of HFpEF.  
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Methodological discussion 
 The rationale underlying this work is grounded in several premises and 
knowledge gaps. The first premise is that HFpEF continues to be refractory to 
available therapies, with current treatment ESC guidelines highlighting the 
importance of aiming to alleviate symptoms and specifically targeting patient’s 
well-being or other health-related outcomes (Ponikowski et al., 2016). The 
second premise is the awareness of an urgent need for novel approaches not 
only for the treatment and management of HFpEF but also for its prevention by 
the screening and management of the potential modifiable contributing risk 
factors, ultimately to prevent HFpEF (Bobenko et al., 2018; Kondamudi et al., 
2017). The third premise is that physical fitness or physical activity (PA) are 
recognized as key modifiable factors for the prevention of HFpEF and 
management of cardinal symptoms such as exercise intolerance and quality of 
life, which are the main targets currently identified by the ESC guidelines (Chan 
et al., 2016) (Kitzman et al., 2010; Nolte et al., 2015). From a clinical perspective, 
this imposes some challenges that need to be tackled to maximize the health 
care, which leads us to the knowledge gaps that we identified in our literature 
review and thus substantiate the aims of our study. First, it must be considered 
that physical fitness is a multicomponent construct and apart from 
cardiorespiratory fitness (CRF), we do not know how HFpEF affects the other 
components or which of these is better representative of health-related outcomes 
such as quality of life. To appraise this issue in Study I, we selected four tests 
from the physical fitness test battery for seniors proposed by Rikli and Jones (Rikli 
& Jones, 2013). We choose the 8-foot up and go test (8FUG) to assess dynamic 
balance and mobility, the 6-minute walk test (6MWT) to assess CRF, the handgrip 
strength test to assess upper body strength, and body mass index to assess body 
composition. These tests are widely used and representative of the different 
physical fitness components, there are reference standard values for 
comparison, they are easy to apply on the clinical setting and they are highly 
related to the daily activity demands of the senior population, which is the most 
representative population segment affected by HFpEF. The current approach 
strengthens this study once that previews studies in HFpEF patients only 
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evaluated one or two physical fitness components (CRF and body composition) 
(Edelmann et al., 2011; Kitzman et al., 2010).  
Similarly to physical fitness, quality of life is also a multidimensional 
construct, and therefore can also be assessed according to different dimensions 
(e.g. general, emotional and physical) (The World Health Organization Quality of 
Life Assessment Group, 1998). The most frequent instruments used to assess 
health-related quality of life in patients with HFpEF are The 36-Item Short-Form 
Health Survey (SF-36) and the Minnesota Living With Heart Failure 
Questionnaire (MLHFQ) (Edelmann et al., 2011; Kitzman et al., 2013; Nolte et 
al., 2015). In Study I, we choose the MLHFQ because it encompasses the 
different dimensions of QoL (such as general, physical and the emotional) and it 
was specifically designed and validated to assess patient’s perception of the 
impact of HF signs and symptoms on their life (Rector & Cohn, 1992). 
A second identified gap is related to the methods and instruments used to 
assess PA, the quality and robustness of the information they provide and their 
usefulness in clinical context. In order to provide tailored counselling and 
prescription to HFpEF patients, it is crucial that the instruments to measure PA 
levels are accurate and reliable. In epidemiological studies encompassing large 
samples as well as in clinical settings, questionnaires are often used to assess 
and monitor PA levels. However, in healthy and unhealthy populations, PA data 
measured by questionnaires are not strongly associated with those obtained with 
objective measurement instruments, for instance those resulting from 
accelerometer evaluation (Lee et al., 2011). In addition, the evaluation of PA by 
questionnaires does not allow to obtain information on the entire spectrum of 
physical activities performed in the everyday life (Prince et al., 2008). This is a 
major flaw to the knowledge of the real PA patterns of HFpEF patients and thus 
limits its use for counselling and control of PA in clinical settings. Moreover, PA 
assessment by questionnaires are based on recall, and this is probably one of 
the main reasons to the observed weak-to- mild associations with the data 
gathered from more objective instruments. Indeed, for many subjects and 
specially for the advanced aged ones it is not easy to have an accurate and 
reliable perception of the amount and intensity of PA they performed (Cheung et 
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al., 2011). Beyond the aforementioned, there is no specific PA questionnaire 
validated to assess PA in HFpEF patients. On its turn, accelerometers provide 
accurate and reliable information regarding daily PA levels and the intensities at 
which it is performed (Gorman et al., 2014), although their use involves some 
financial cost and requires expertise to manage the provided data (Troiano, 
2005). In order to supply the need of a reliable and valid instrument to assess PA 
levels in the clinical practice for HFpEF patients, we compared PA levels from 
IPAQ (short form) with accelerometer-derived data (Actigraph GT3X). The short 
form of IPAQ was selected because it was validated against accelerometer 
measurements in 12 countries with several populations (Craig et al., 2003), and 
was developed by the World Health Organization to guide policy development 
related to health-enhancing physical activity (http://www.ipaq.ki.se). Regarding 
the accelerometer, we opted for the Actigraph GT3X, which has been used in 
hundreds of large-scale studies (Martin et al., 2014; Shiroma et al., 2013), but 
was never used to study and assess PA in HFpEF patients. This specific 
accelerometer was selected because it has an activity monitor that can capture 
body accelerations in three different planes of motion, such as vertical, antero-
posterior and medio-lateral (Zisko et al., 2015). The device provides activity 
counts as a composite vector magnitude (VM) of these three axes (Sasaki et al., 
2011). By measuring motion in three different planes, the GT3X accelerometer 
has the ability of quantify PA levels more accurately than common uniaxial 
accelerometers (Kelly et al., 2013). While for the above-mentioned reasons we 
believe that PA assessed through triaxial accelerometry strengthens our study, it 
posed a methodological challenge as there are no cut-point validated to define 
PA intensities in HFpEF patients. In order to overcome that issue, we opted to 
select cut-points previously validated in older adults using the same device 
(Santos-Lozano et al., 2013), once the clinical population included in our study 
was mostly elderly (76±6 years). Therefore, we can compare the obtained results 
with an aged matched reference population. However, we must recognize that 
these cut-points were developed in a laboratory setting during treadmill walking 
and not in free-living conditions (Santos-Lozano et al., 2013). This is a major 
issue to consider once cut-points determined in laboratory settings were 
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demonstrated to be less accurate to capture movements performed in free-living 
conditions, which may misclassify the time spent in each PA intensity (Sasaki et 
al., 2016). In order to overcome this limitation, we used a low frequency extension 
filter, which was shown to be more sensitive to capture slower and less intense 
body movements, such as those that frequently occur in daily life activities 
(Migueles et al., 2017). 
Another methodological issue that deserves consideration is the sample 
size in Study I and Study II, which was small, and thus, limits the generalization 
of our results. However, we must highlight that the clinical features of our sample 
are very similar to the clinical features typically presented in epidemiological and 
clinical studies with HFpEF patients (Ponikowski et al., 2016; Vaduganathan et 
al., 2016). Patients with HFpEF are more likely to be women and old aged, with 
a higher prevalence of comorbidities such as hypertension, dyslipidaemia and 
obesity (Dunlay et al., 2017). Similarly, patients include in the present work were 
predominantly elders (76±6 years old), mostly female (71%) and had a greater 
prevalence of comorbidities [e.g. hypertension (92%), dyslipidemia (71%) and 
obesity (58%)]. In addition, our patients presented reduced exercise capacity, as 
evidenced from the distance performed on the 6MWT (313±91 meters), the 
elevated levels of natriuretic peptides (288.9±191.5 pg/mL), and the cardiac 
structural alterations (left atrial volume index= 44.2 ±11.7 mL/m2; left ventricular 
mass index= 231.3±94.5 g/m2). 
Although there is some evidence that exercise training can improve diastolic 
function in HFpEF patients (Chan et al., 2016), the mechanisms underlying this 
improvement are still unknown. The use of animal models of disease is 
particularly important because of the limited access to human cardiac tissue 
samples (Vaduganathan et al., 2016). None of the current animal models of 
HFpEF fully mimics the spectrum of changes found in the human phenotype such 
as the concomitant presence of comorbidities, cardiac functional and structural 
changes, and exercise intolerance (Lourenco et al., 2018). Recently, a new 
HFpEF model using the obese ZSF1 rat has been proposed (Hamdani et al., 
2013). It is considered a robust model as these animals display hypertension, 
obesity, type 2 diabetes, insulin resistance, hyperinsulinemia, 
  
CRISTINE SCHMIDT | HEART FAILURE WITH PRESERVED EJECTION FRACTION: FROM PROGNOSIS TO CARDIAC FUNTION | 
 
125 
hypertriglyceridemia and hypercholesterolaemia (Hamdani et al., 2013). Over 
time, this cardiometabolic risk model develops the main features found in humans 
diagnosed with HFpEF: i) reduced exercise tolerance, ii) preserved systolic 
function (LVEF, LVdP/dtmax, and the slope of ESPVR) and iii) diastolic dysfunction 
(higher E/e’, prolonged tau, elevated LVEDP, an upwards shift of LV diastolic 
pressure-volume relationship, and higher LV diastolic chamber stiffness 
constant) (Hamdani et al., 2013; Leite et al., 2015). Therefore, in Study III, we 
used the ZSF1 obese animal model of HFpEF to evaluate the effects of exercise 
training on LV function, structure and underlying molecular changes. Given that 
ZSF1 rats are obese, present exercise intolerance and impaired cardiac function, 
we anticipated that it would be difficult for these animals to complete an exercise 
training protocol. In attempt to ensure compliance, an aerobic continuous training 
of low-intensity protocol consisting of in running in a treadmill at 20 m/min, 60 
min/day, 5 days per week, during a period of 5 weeks was selected.  
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Discussion of the main results  
The present thesis had three important findings. Data from Study I showed 
that physical fitness, particularly dynamic balance and agility, was positively 
correlated with all dimensions of quality of life, outperforming all the other 
components of physical fitness. Moreover, Study II demonstrated that IPAQ-SF 
is not an accurate instrument to assess PA levels in HFpEF patients, and that 
MVPA was the single PA intensity category positively associated with functional 
capacity and quality of life. Finally, Study III showed that exercise training 
improves exercise capacity, modulates LV stiffness and reduces circulating levels 
of inflammatory, oxidative stress and endothelial dysfunction markers.  
 
Association between different components of physical fitness and 
dimensions of quality of life in HFpEF patients 
 As already stated, several studies have shown that physical fitness is an 
important determinant of quality of life in HFpEF (Kitzman et al., 2010; Nolte et 
al., 2015). Up to date, it was only established that higher levels of CRF are 
associated with a better quality of life, mainly the physical dimension (Edelmann 
et al., 2011; Kitzman et al., 2010). Our study adds novelty by showing that 
dynamic balance and mobility is the single physical fitness component associated 
with all dimensions of quality of life (general, physical and emotional). In addition, 
our data revealed that dynamic balance and mobility outperforms CRF in 
capturing HFpEF patients' quality of life. The capacity of the 8FUG test to better 
identify patient’s quality of life might be explained by the wide range of physical 
factors that influence the performance in this test (lower body strength, balance, 
walking, agility and gait speed) (Rikli & Jones, 2013), which are also analogous 
to the required in the normal daily tasks of an independent and autonomous life 
(Mlinac & Feng, 2016) and perceived as the most important determinants of 
patient’s quality of life. Although CRF assessed by maximal or symptom-limited 
graded exercise tests or by the six-minute walk test were proven to be associated 
with prognostic indicators and able to discriminate the grade of severity of disease 
course, it might be possible that the continuous nature of the exercise might not 
be sensitive to show an association with the dimensions of perceived quality of 
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life that is probably more influenced by the intermittent physical demands related 
of household activities and commuting. In this sense, results from Study I gave 
some insights from a new instrument to be used in the clinical setting, since the 
underlying capacities are important to monitor HFpEF patients’ quality of life 
correlates. Despite that, the 8FUG test has the advantage of being simple to 
administer, requiring a limited space, minimal equipment (i.e. markers on the floor 
and a chair) and it is easily understand by patients (Wilkinson et al., 2018). 
Therefore, we recommend the use of the 8FUG test on clinical practice in 
combination with the assessment of patients’ quality of life.  
 
The utility of IPAQ short form to measure PA levels in HFpEF patients 
Despite the evidence shows that questionnaires are valid and reliable in 
measuring PA, their correlation with accelerometers-derived data is far from 
satisfactory (Koolhaas et al., 2018; Lee et al., 2011; Prince et al., 2008; Skender 
et al., 2016), which limits PA-based decisions in the clinical setting regarding 
counselling and recommendations. Our results corroborate previous findings in 
the general population, showing that the measures derived from IPAQ-SF 
underestimates sedentary time and overestimates time spent in MVPA in HFpEF 
patients, and also showed poor agreement between self-reported and 
accelerometer-derived PA measures. Therefore, based on our findings, the use 
of IPAQ-SF should not be recommended to support accurate recommendations 
in this specific population. For clinical purposes, at an individual level, it is 
important to have accurate and reliable PA information to assess the risk level 
and to prescribe life-style changes. Therefore, the use of accelerometers to 
assess daily PA levels in HFpEF patients seems to have a particular importance. 
Objective measures can avoid bias related with subjective measures, especially 
in populations that have limited physical function and no experience performing 
PA. Moreover, self-reported measures depend on recall which can be biased 
specially in older patients (Prince et al., 2008). Nevertheless, although 
accelerometry is considered a better methodology to assess PA when compared 
to questionnaires, it cannot provide comprehensive information in terms of type 
and context in which PA occur. In this sense, to provide tailored 
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recommendations in the clinical setting, we suggest the use of accelerometers 
together with a diary log to better characterize patients’ PA levels. 
 
Patterns of PA and sedentary time in HFpEF patients, and its association 
with prognostic indicators 
Given the growing recognition of the impact of PA levels in the prognosis of 
HFpEF patients, a rigorous characterization of their patterns is crucial for 
prescribing tailored life-style changes to improve well-being and quality of life, 
and to mitigate/attenuate the disease progression. In the study II we observed 
that HFpEF patients spent most of their waking time in sedentary behaviours 
while their daily activity was mainly comprised of light physical activity, and just a 
few minutes in MVPA. Increased sedentary behaviours and decreased time 
spend in MVPA are both associated with worse clinical outcomes in HFpEF 
patients (Hegde et al., 2017; Snipelisky et al., 2017). Interestingly, our study adds 
the novelty that only time spent in MVPA was significantly associated with 
important clinical outcomes as VO2, 6MWT performance and QoL, but not with 
E/e´ or BNP levels. Thus, it seems that intensity is a requirement for significantly 
impacting the patient’s prognosis. Corroborating this hypothesis, it was recently 
shown a dose-response relationship between MVPA and risk of hospitalization 
or mortality in HFpEF patients (Hegde et al., 2017). Despite that, it was already 
shown that any increase in the amount of PA may translate into some health 
benefits (Physical Activity Guidelines Advisory Committee Scientific Report, 
2018). Taking together, these data emphasise the clinical importance to educate 
patients about the importance of engaging in more MVPA throughout the day and 
to reduce their time spent in sedentary behaviours in order to achieve higher 
health-related benefits.  
 
Effects of exercise training in an animal model of HFpEF 
Exercise training is emerging as an important ally for the clinical 
management of health-related outcomes in HFpEF patients. However, the 
literature thus far cannot elucidate the mechanisms by which exercise training 
can induce improvements in HFpEF patients. Current published data suggests 
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that the improvements in VO2peak found in HFpEF patients after an exercise 
training program are mainly due to non-cardiac peripheral adaptations, as no 
study has yet shown to improve peak cardiac output (Fu et al., 2016; Haykowsky 
et al., 2012). However, both clinical (Dieberg et al., 2015; Pearson et al., 2017) 
and pre-clinical studies (Hidalgo et al., 2014; Marshall et al., 2013) support the 
hypothesis that exercise training improves diastolic function in HFpEF setting, 
which may also account for an improved acute exercise response. Results from 
Study III show that exercise training can improve exercise capacity and 
enhances cardiac function by decreasing cardiomyocyte passive tension and by 
attenuating LV fibrosis in HFpEF animals. These results provide novel 
mechanistic insights into the benefits of regular exercise training in a clinically 
translational animal model of HFpEF. Understanding the pathways that mediate 
these benefits, and learning how to manipulate them in vivo, could yield novel 
therapeutic approaches based on agents that mimic or potentiate the 
physiological benefits of exercise. As mentioned in the first chapter (General 
Introduction, page 9) low-grade chronic systemic inflammation derived from 
comorbidities is responsible for coronary microvascular inflammation, which 
might lead to myocardial dysfunction and remodelling. Our results in Study III 
suggest that beyond the improvements in cardiomyocyte passive tension and LV 
fibrosis, regular exercise training was able to attenuate systemic inflammation 
and to diminish circulating markers of oxidative stress and endothelial 
dysfunction. Collectively, these results empower the hypothesizes that low-grade 
chronic systemic inflammation is the main trigger of HFpEF. Therefore, our 
results confirm the pleiotropic effects of exercise training, namely its anti-
inflammatory effect, which might modulate improvements in cardiac function by 
interfering in the cascade of events that lead to decreased diastolic left ventricular 
stiffness and interstitial fibrosis. Overall, results from Study III suggest that 
exercise training may be a particularly powerful adjuvant treatment option to 
HFpEF patients, but clinical studies are needed to clarify the best type of training, 
frequency and intensity in large populations with HFpEF. 
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CHAPTER V 
 
 
CONCLUSIONS AND FUTURE DIRECTION 
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CONCLUSIONS 
 
Based on the general conclusions of each study that were presented in this 
thesis, it is possible to outline the following major conclusions: 
 
• Physical fitness, particularly dynamic balance and mobility, is 
associated with all dimensions of quality of life in patients with 
HFpEF. In addition, dynamic balance and mobility outperforms 
others physical fitness components in capturing HFpEF patients' 
quality of life. 
• The IPAQ-SF underestimates sedentary time and overestimates 
time spent in MVPA in patients with HFpEF. Patients spent only a 
minority of their daily time involved in MVPA, which was the only PA 
intensity positively associated with functional capacity and quality of 
life. 
• Moderate exercise training improves exercise capacity and 
attenuates left ventricle diastolic stiffness in the ZSF1 obese animal 
model of HFpEF. This was paralleled by reduced circulating levels of 
inflammatory cytokines and markers of endothelial dysfunction and 
oxidative stress. 
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FUTURE DIRECTIONS 
 
Further prospective cohort studies with a larger sample size are needed 
to strengthen or refute our conclusions that dynamic balance and mobility is more 
discriminative to capture HFpEF patients' quality of life, and to verify the 
agreement between PA measurements from the IPAQ-SF and PA measures 
derived from triaxial accelerometer.  
In addition, experimental studies exploring the molecular changes 
underlying the cardiomyocyte’s intrinsic and extrinsic changes induced by 
exercise training are fundamental as they may lead to the identification of 
therapeutic molecular targets.  
Moreover, different exercise training protocols with the ZSF1 animal model 
are also required in order to better understanding the dose-response relationship 
between exercise training and HFpEF improvements.   
  
  
CRISTINE SCHMIDT | HEART FAILURE WITH PRESERVED EJECTION FRACTION: FROM PROGNOSIS TO CARDIAC FUNTION | 
 
140 
 
 
  
  
CRISTINE SCHMIDT | HEART FAILURE WITH PRESERVED EJECTION FRACTION: FROM PROGNOSIS TO CARDIAC FUNTION | 
 
141 
 
 
 
APPENDICES 
  
  
CRISTINE SCHMIDT | HEART FAILURE WITH PRESERVED EJECTION FRACTION: FROM PROGNOSIS TO CARDIAC FUNTION | 
 
142 
 
  
CRISTINE SCHMIDT | HEART FAILURE WITH PRESERVED EJECTION FRACTION: FROM PROGNOSIS TO CARDIAC FUNTION | 
 
143 
As seguintes questões procuram avaliar em que medida a sua insuficiência cardíaca (problema cardíaco) 
afetou a sua vida no último mês (4 semanas). Em cada questão, assinale com um círculo o número que 
melhor reflete o modo como a sua vida foi afetada (0, 1, 2, 3, 4 ou 5). Se alguma questão não se aplicar a 
si, assinale o número 0 (zero). 
No último mês (4 semanas), a sua insuficiência 
cardíaca impediu-o(a) de viver como queria porque… 
 
1. lhe provocou inchaço nos tornozelos ou pernas?                    
2. o(a) obrigou a sentar-se ou deitar-se para  
descansar durante o dia?                                                              
3. lhe causou dificuldade em caminhar ou subir escadas?  
4. lhe dificultou a realização das tarefas domésticas  
ou no quintal? 
5. dificultou as suas saídas de casa? 
6. o impediu de dormir bem de noite? 
7. dificultou o seu relacionamento e as atividades  
com amigos ou familiares? 
8. dificultou a realização das suas atividades profissionais? 
9. dificultou as suas atividades de lazer, desportivas  
ou os seus passatempos? 
10. dificultou a sua atividade sexual? 
11. o(a) fez comer menos quantidade das comidas  
de que gosta? 
12. lhe causou falta de ar? 
13. o(a) fez sentir-se cansado(a), fatigado(a) ou  
com pouca energia? 
14. o(a) obrigou a internamento hospitalar? 
15. lhe criou despesas com cuidados médicos? 
16. fê-lo(a) sentir efeitos secundários provocados  
pela medicação? 
17. fê-lo(a) sentir-se um fardo para a família e amigos? 
18. fê-lo(a) sentir perda de autocontrole na sua vida?  
19. fê-lo(a) sentir-se preocupado(a)? 
20. lhe dificultou a concentração ou a memória?  
21. fê-lo(a) sentir-se deprimido(a) 
 
 
                Muito                        
    Não         Pouco                            Muito 
0             1        2       3       4       5  
0             1        2       3       4       5  
0             1        2       3       4       5  
0             1        2       3       4       5  
0             1        2       3       4       5  
0             1        2       3       4       5  
0             1        2       3       4       5  
0             1        2       3       4       5  
0             1        2       3       4       5  
0             1        2       3       4       5  
0             1        2       3       4       5  
0             1        2       3       4       5  
0             1        2       3       4       5  
0             1        2       3       4       5  
0             1        2       3       4       5  
0             1        2       3       4       5  
0             1        2       3       4       5  
0             1        2       3       4       5  
0             1        2       3       4       5  
0             1        2       3       4       5  
0             1        2       3       4       5  
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Atividade Física 
Estamos interessados em conhecer os diferentes tipos de atividade física, que as pessoas 
fazem no seu quotidiano.  
As questões que lhe vou colocar, referem-se à semana imediatamente anterior, considerando 
o tempo em que esteve fisicamente ativo/a. Por favor, responda a todas as questões, mesmo 
que não se considere uma pessoa fisicamente ativa. Vou colocar-lhe questões sobre as 
atividades desenvolvidas na sua atividade profissional e nas suas deslocações, sobre as 
atividades referentes aos trabalhos domésticos e às atividades que efetuou no seu tempo livre 
para recreação ou prática de exercício físico / desporto.                                                                      
Ao responder às seguintes questões considere o seguinte: 
Actividades físicas vigorosas referem-se a atividades que requerem um esforço físico 
intenso que fazem ficar com a respiração ofegante. 
Actividades físicas moderadas referem-se a atividades que requerem esforço físico 
moderado e tornam a respiração um pouco mais forte que o normal. 
Ao responder às questões considere apenas as actividades físicas que realize durante pelo 
menos 10 minutos seguidos 
 
Q.1 Diga-me por favor, nos últimos 7 dias, em quantos dias fez actividades físicas 
vigorosas, como por exemplo, levantar objetos pesados, cavar, ginástica aeróbica, nadar, 
jogar futebol, andar de bicicleta a um ritmo rápido? 
 Dias 
 
Q.2 Nos dias em que pratica actividades físicas vigorosas, quanto tempo em média dedica 
normalmente a essas actividades? 
 
  Horas     Minutos (por dia) 
     
 
Q.3 Diga-me por favor, nos últimos 7 dias, em quantos dias fez actividades físicas 
moderadas como por exemplo, carregar objectos leves, caçar, trabalhos de carpintaria, 
andar de bicicleta a um ritmo normal ou ténis de pares? Por favor não inclua o “andar”.    
 Dias  
Q.4 Nos dias em que faz actividades físicas moderadas, quanto tempo em média dedica 
normalmente a essas actividades? 
  Horas     Minutos (por dia) 
     
Q.5 Diga-me por favor, nos últimos 7 dias, em quantos dias andou pelo menos 10 minutos 
seguidos? 
 Dias  
Q.6 Quanto tempo no total, despendeu num desses dias, a andar/caminhar? 
  Horas     Minutos (por dia)  
    
Q.7 Diga-me por favor, num dia normal quanto tempo passa sentado? Isto pode incluir o 
tempo que passa a uma secretária, a visitar amigos, a ler, a estudar ou a ver televisão. 
  Horas     Minutos (por dia)  
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